Meta-epidemiologic consideration of confounding for health care decision making by Ewald, Hannah
Meta-epidemiologic consideration of 
confounding for health care decision 
making 
 
 
Inauguraldissertation 
zur 
Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
 
von 
 
Hannah Ewald 
aus Amberg, Deutschland 
 
Basel, 2018 
 
Originaldokument gespeichert auf dem Dokumentenserver der Universität 
Basel 
edoc.unibas.ch 
Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät 
auf Antrag von  
 
 
Prof. Dr. Marcel Tanner (Fakultätsverantwortlicher) 
PD Dr. med. Lars G. Hemkens (Dissertationsleiter) 
Prof. Dr. med. Atle Fretheim (Koreferent) 
 
 
 
 
 
 
Basel, den 27. März 2018 
Prof. Dr. Martin Spiess (Dekan) 
 
  
Table of contents 
 
Acknowledgements ................................................................................................................................. vi 
Abbreviations ......................................................................................................................................... vii 
Plain language summary ......................................................................................................................... ix 
Introduction ............................................................................................................................................. 1 
Aims ..................................................................................................................................................... 3 
Objectives ............................................................................................................................................ 4 
Doctoral Manuscripts .............................................................................................................................. 5 
I “Interpretation of epidemiologic studies very often lacked adequate consideration of confounding”6 
Status ................................................................................................................................................... 6 
Abstract ............................................................................................................................................... 6 
What is new? ....................................................................................................................................... 7 
Introduction ......................................................................................................................................... 8 
Methods .............................................................................................................................................. 8 
Results ............................................................................................................................................... 11 
Discussion .......................................................................................................................................... 12 
Conclusion ......................................................................................................................................... 14 
Conflict of interests ........................................................................................................................... 15 
Authors’ contribution ........................................................................................................................ 15 
Funding .............................................................................................................................................. 15 
Role of the funding source ................................................................................................................ 15 
Data sharing....................................................................................................................................... 15 
Ethical approval ................................................................................................................................. 15 
References ......................................................................................................................................... 16 
Tables ................................................................................................................................................ 18 
Figures ............................................................................................................................................... 23 
Webappendix .................................................................................................................................... 24 
II “Impact of Marginal Structural Models as enhanced confounder control methods in non-randomized 
comparative effectiveness: a meta-epidemiologic study” .................................................................... 25 
Status ................................................................................................................................................. 25 
Abstract ............................................................................................................................................. 25 
What is known on this topic: ............................................................................................................. 27 
What does it add: .............................................................................................................................. 27 
Introduction ....................................................................................................................................... 28 
Methods ............................................................................................................................................ 28 
Results ............................................................................................................................................... 31 
Discussion .......................................................................................................................................... 33 
Conclusion ......................................................................................................................................... 34 
Acknowledgements ........................................................................................................................... 36 
Data sharing....................................................................................................................................... 36 
Declaration of competing interests ................................................................................................... 36 
Authors’ contribution ........................................................................................................................ 36 
Funding .............................................................................................................................................. 36 
Role of the funding source ................................................................................................................ 36 
Transparency declaration .................................................................................................................. 36 
Ethical approval ................................................................................................................................. 37 
References ......................................................................................................................................... 38 
Tables ................................................................................................................................................ 42 
Figures ............................................................................................................................................... 47 
Webappendix .................................................................................................................................... 49 
III “Treatment effects from marginal structural models in randomized clinical trials: meta-
epidemiological analysis” ...................................................................................................................... 50 
Status ................................................................................................................................................. 50 
Abstract ............................................................................................................................................. 50 
Introduction ....................................................................................................................................... 51 
Methods ............................................................................................................................................ 52 
Results ............................................................................................................................................... 54 
Discussion .......................................................................................................................................... 55 
Conclusion ......................................................................................................................................... 58 
Acknowledgments ............................................................................................................................. 59 
Contributors ...................................................................................................................................... 59 
Funding .............................................................................................................................................. 59 
Role of the funding source ................................................................................................................ 59 
Transparency declaration .................................................................................................................. 59 
Ethical approval ................................................................................................................................. 59 
References ......................................................................................................................................... 60 
Tables ................................................................................................................................................ 65 
Figures ............................................................................................................................................... 71 
Webappendix 1 ................................................................................................................................. 74 
Webappendix 2 ................................................................................................................................. 75 
Webappendix 3 ................................................................................................................................. 78 
Discussion .............................................................................................................................................. 81 
Overall findings .................................................................................................................................. 81 
Findings in context ............................................................................................................................ 81 
Limitations and future research ........................................................................................................ 82 
What we can do now ......................................................................................................................... 83 
Closing Remarks ................................................................................................................................ 84 
References ............................................................................................................................................. 85 
Appendix I – Further Manuscripts published during doctoral studies .................................................. 87 
Systematic review and simulation study of ignoring clustered data in surgical trials ...................... 87 
Off-label treatments were not consistently better or worse than approved drug treatments in 
randomized trials ............................................................................................................................... 88 
Comparative effectiveness of tenofovir in HIV-infected treatment-experienced patients: systematic 
review and meta-analysis .................................................................................................................. 89 
Colchicine and prevention of cardiovascular events ......................................................................... 90 
The clinical effectiveness of pneumococcal conjugate vaccines – a systematic review and meta-
analysis of randomized controlled trials ........................................................................................... 91 
Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-
analysis .............................................................................................................................................. 93 
Colchicine for prevention of cardiovascular events .......................................................................... 94 
Comparative effectiveness of Tenofovir in treatment-naïve HIV-infected patients: systematic review 
and meta-analysis .............................................................................................................................. 95 
Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection .... 96 
Appendix II – Short curriculum vitae: Hannah Ewald ............................................................................ 98 
Education ........................................................................................................................................... 98 
Professional Experience .................................................................................................................... 98 
Scientific Awards ............................................................................................................................... 98 
List of conferences with presentations ............................................................................................. 98 
List of teaching activities ................................................................................................................... 98 
 
 
  vi 
Acknowledgements 
 
I would like to thank everyone who helped realize this project.  
Special thanks go to: 
Lars G Hemkens, for excellent supervision and great humor, who never failed to notice my nightly rides 
around the office on a magical broomstick or my sophisticated conversations with the office’s unofficial 
pet raven. 
Heiner C Bucher, for giving me the opportunity to do my PhD at the Institute for Clinical Epidemiology 
& Biostatistics, and to “pack my suitcase full of scientific tools”. 
John PA Ioannidis, for sharing his knowledge and insight and making me feel part of a much bigger 
picture. 
Aviv Ladanie, my smart co-PhD student, whose help in coding saved me from premature-jumping-out-
of-the-window. 
Dominik Glinz, for reminding me that coffee breaks have a purpose – even if I don’t drink coffee. 
Kimberly Mc Cord, for secretly providing me with the best chocolate chip cookies in the world when 
I’m not trying to enhance my brain function with a zero-added-sugar diet. 
Mirco Wedel, for his unconditional support and inspiring discussions on statistical issues, even at 4 in 
the morning. 
My family and friends, for believing in me. 
The world is a better place with you all in it. 
  
  vii 
Abbreviations 
 
ACTG AIDS Clinical Trial Group 
AIDS Acquired Immune Deficiency Syndrome 
ARISTOTLE Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial 
Fibrillation trial 
ART Anti-retroviral therapy 
ATHENA AIDS Therapy Evaluation Netherlands 
BL Baseline 
BMJ The British Journal of Medicine 
CALERIE Comprehensive Assessment of the Long-term Effects of Reducing Intake of 
Energy 
CD4 Cluster of differentiation 4 
CDC-C Centers for Disease Control and Prevention classification system for HIV-
infection, category C: severely symptomatic 
CEB Basel Institute for Clinical Epidemiology and Biostatistics 
CER Comparative effectiveness research 
CHD Coronary heart disease 
CI Confidence interval  
CMAJ Canadian Medical Association Journal 
COREYA study COhort with REYAtaz study 
CoRIS Cohorte de la Red de Investigación en SIDA 
CVD Cardiovascular disease 
DOPPS Dialysis Outcomes and Practice Patterns Study 
EQUATOR Enhancing the QUAlity and Transparency Of health Research 
ESRD End stage renal disease 
EVOO Extra virgin olive oil 
FHDH-ANRS CO4 French Hospital Database on HIV—Agence Nationale de Recherches sur le SIDA 
GEMES Grupo Español Multicéntrico para el Estudio de Seroconvertores-Haemophilia 
GPRD General Practice Research Database 
GRADE Grading of Recommendations Assessment, Development and Evaluation 
HAART Highly active anti-retroviral therapy 
HIV Human immunodeficiency virus 
HR Hazard ratio 
ICH International Conference on Harmonisation 
IF Impact factor 
IPCW Inverse probability of censoring weighting 
IPTW Inverse probability of treatment weighting 
IPW Inverse probability weighting 
IQR Interquartile range  
ISAARV Initiative Sénégalaise d’Accès aux Medicaments Anti-rétroviraux 
ITT Intention-to-treat 
JAMA Journal of the American Medical Association 
  viii 
MACS Multicenter AIDS Cohort Study 
MEDLINE Medical Literature Analysis and Retrieval System Online 
MSM Marginal structural models  
NA Not applicable 
NSCLC Non-small-cell lung cancer 
OEDTR Austrian Dialysis and Transplant Registry 
OR Odds ratio 
PHS Physicians’ Health Study 
PICO Patient – Intervention  – Comparison  – Outcome  
PISCIS Proyecto para la Informatización del Seguimiento Clinico-epidemiológico de la 
Infección por HIV y SIDA 
PLOS Public Library of Science 
PP Per protocol 
PPHS PhD Educational Platform Health Sciences 
PREDIMED Primary Prevention of Cardiovascular Disease with a Mediterranean Diet 
RCT Randomized controlled trial 
RECORD REporting of studies Conducted using Observational Routinely collected Data 
ROBINS Risk Of Bias In Non-randomised Studies of Interventions 
ROR Ratio of odds ratios  
SHCS Swiss HIV Cohort Study 
SNMs Structural nested models 
STROBE Strengthening the Reporting of Observational Studies in Epidemiology  
Swiss TPH Swiss Tropical and Public Health Institute 
THIN The Health Improvement Network 
UK United Kingdom 
UK CHIC United Kingdom Collaborative HIV Cohort 
US VACS-VC United States Veterans Aging Cohort Study–Virtual Cohort 
USA United States of America 
USRDS US Renal Data System 
WHI Women’s Health Initiative 
WHS Women’s Health Study  
 
  
  ix 
Plain language summary 
 
As patients, we all want to believe that there is the right medical solution for every ailment and that 
our doctor knows best. What we usually don’t know is that our doctor’s knowledge is based on 
experience and on evidence. However, the evidence can be flawed, exaggerated, or may not actually 
apply to us. While there are many things that can go wrong in clinical studies, the main focus of this 
dissertation is on the concept of confounding. Confounding occurs when a specific exposure and 
outcome have a common cause. For example, more breast cancer patients receiving surgery as the 
observed “exposure” survive than those receiving chemotherapy. Concluding that surgery is better for 
survival may, however, be confounded by cancer stage because those who were operated on had a 
less advanced cancer stage and thus were more likely to survive to begin with. Minimizing the impact 
of such confounding in research studies on treatment effects is important because it can alter the 
estimates of a treatment effect and thus may lead to wrong conclusions and ultimately to wrong 
treatment decisions. 
For many health topics, there are myriads of studies available and whether or not their results can give 
us reliable answers to what we want to know depends on a variety of factors. The most important 
factor is the study design. Randomized controlled trials (RCTs) are the current gold standard to produce 
evidence for treatment decisions. They measure the causal effect of a treatment versus a control on a 
specific outcome. The key element is that study participants are randomly assigned to treatment or 
control (which could be a placebo or another treatment). The randomization tries to balance all known 
(such as age) and unknown characteristics (such as undiagnosed diseases) of the participants which 
means that they also balance all known and unknown confounding factors. The only difference 
between the participant groups will then be the allocation to a treatment or control. This would be the 
perfect study design if the circumstances were ideal, i.e. if every participant adhered to the assigned 
treatment and stayed on the study until the end. In reality, the participants often do not adhere (e.g. 
because the exercise program of a weight-loss study is too demanding) or they become lost to follow-
up (e.g. because they moved away or did not want to be on the study anymore). However, not every 
clinical question can be answered in an RCT. Another important research design are observational 
studies, where the exposure of patients to an intervention or a control is not decided by the study 
investigators (thus observational) and may thus depend on a number of other known and unknown 
factors, e.g. doctors’ decisions or patient’s preferences. This study design is very prone to confounding 
and requires careful statistical analyses. Statistical methods can then be used to retrospectively 
address issues like confounding or confounding that changes over time. One such statistical method is 
marginal structural models (MSM). MSM allow a causal interpretation of results under the 
assumptions that all confounding factors are known, correctly measured and properly implemented in 
the statistical models. However, even with the latest statistical methods, RCTs and observational 
studies may not give the same answer when trying to solve the same question. Hence, the aims of the 
doctoral projects were 1) to evaluate the extent to which confounding is actively considered in the 
conclusions from observational studies; 2) to evaluate the agreement of treatment effects from non-
randomized studies using MSM with reported effects from RCTs on the same topic; 3) to evaluate when 
MSM is used in RCTs and how these results differ from the main (non-MSM) results of the same trial. 
First, we assessed the scope of the issue within the health professionals’ literature. Are authors of 
scientific papers aware of the problem of confounding for the interpretation of their results and do 
they present their results in light of its possible impact? Second, if observational studies use MSM to 
  x 
reduce the impact of confounding and allow a causal interpretation, the results should be similar to 
those from RCTs on the same clinical question. To assess how well they agree, we used established 
approaches to compare the effects, for example we determined how often the effects from both 
designs indicated concordantly that a treatment is beneficial or not. Third, we conducted an empirical 
analysis of where and why MSM is used to analyze randomized comparisons, a rather new and 
emerging approach to address confounding within randomized trials, and how these results compare 
to non-MSM results from the same trial. 
We found that observational studies in general tend to have unsatisfactory or no discussion of 
confounding at all. If confounding was mentioned, it was either deemed irrelevant for the respective 
research or results are not brought in context of necessary cautious interpretation. Studies that did, 
however, report possible limitations due to confounding were actually cited more by other researchers 
than studies that deemed an influence due to confounding unlikely. This means research that is 
carefully reported may have more impact on science than other research. 
When MSM was applied to observational study data, the effects often had opposite directions (i.e. one 
showed harm and the other benefit of the intervention) and were more favorable for the experimental 
treatment than in randomized studies on the same research question. This was even more so when 
the studies focused on informing health care decision making rather than statistical methodology. 
MSM was applied to RCTs to minimize the influence of confounding that arises when study participants 
do not adhere to the protocol. Within the main publication and the publication reporting MSM-based 
results (sometimes the same), authors reported on average 6 analyses for one outcome in the same 
population and at the same point in time. Most of these results, however, pointed in the same 
direction and had more or less similar effect sizes, which means that the clinical interpretation is often 
similar. 
We can never be certain that we know all confounding factors, measured them correctly and 
implemented them correctly in the statistical models. Even research that used causal modelling 
techniques may still come to different answers than RCTs evaluating the same clinical question would. 
Hence, confounding should be more carefully acknowledged in non-randomized research, doing so is 
not associated with lower citation impact. Results from causal modelling can be useful sensitivity 
analyses that can help researchers to get a bigger picture of the impact of other influencing factors. 
Health care decision makers should remain cautious when using non-randomized evidence to guide 
their health care decisions. 
 
  1 
Introduction 
 
In evidence-based medicine, the best available clinical evidence, the clinician’s expertise, and the 
patient’s values and preferences are applied to make an individualized, medical, evidence-based 
decision1. Study designs to gather evidence are frequently classified into two main categories: 
randomized controlled trials (RCTs), where patients are randomly allocated to an intervention or a 
control, and observational studies, where the exposure of patients to an intervention or a control is 
not controlled by the investigators (thus observational) and may thus depend on a number of other 
known and unknown factors, e.g. doctors’ decisions or patients’ preferences2. The estimated effects 
from both study designs can deviate from the true (and unknown) effect of the treatments for many 
reasons including random error and bias. The key advantage of RCTs over observational studies is 
better control of a number of biases. 
Bias is any error that leads to the systematic over- or underestimation of an effect and thus 
systematically undermines the internal validity of a study. Bias is systematic insofar that – other than 
random error – it does not decrease when replicating the study several times or when increasing 
sample size, the result will always deviate from the true effect3 4. Methodologists have defined a large 
number of individual biases, and the definitions are not always clear5 6. One important type of bias is 
selection bias. It arises when groups are not comparable because of an uneven distribution of patient 
characteristics and prognostic factors7-9. For example, if a study concludes that vegetarianism prolongs 
life, that may simply be because compared to non-vegetarians, vegetarians tend to smoke less. This is 
a systematic difference that would introduce selection bias if not controlled for through statistical 
methods (the effect of not smoking would overshadow the effect of not eating meat). While 
observational studies are extremely prone to this bias, RCTs can also be concerned when recruiters 
can guess and alter upcoming treatment allocations, e.g. by lack of allocation concealment leading to 
a broken randomization7-9. Another type of bias is information bias (also called detection or 
measurement bias) which stems from errors in measurement and determination of exposure and 
outcome. As these are essential for most statistical analyses, such errors can result in mislead care3 7. 
RCTs are especially prone to this bias when outcome assessors are not blinded3. Another major bias in 
observational studies is confounding. The concept of confounding generally refers to a problem of 
comparability but it can have different meanings in different scientific fields and eras8 10. In 
epidemiology, a confounder is a factor that influences both the exposure to an intervention and the 
outcome7. For example, cancer stage is a prognostic factor which influences the treatment decision 
but also the chance of survival (Figure 1).  
At the level of study design, RCTs provide methods to control for confounding bias. At the level of 
analysis, a number of statistical methods are available that aim to control for confounding bias in 
observational studies: Traditional approaches to control the influence of confounding are, for example, 
restriction, matching, stratification, multivariate regression, and propensity scores7 11 12. These 
techniques focus on balancing characteristics between comparison groups at baseline. This can be as 
simple as in the cancer stage example (Figure 1), but confounders cannot always be clearly determined 
or remain unknown. For example, a study finds a strong association between frequently taking 
vacations and living longer13. It is easy to imagine that stress reduction and increased physical activities 
may have a positive impact on health and hence on lifespan. A possible confounder could be stress 
level at work: people with very demanding jobs may not take vacation as often but may have a higher 
  2 
risk for cardiovascular disease which could shorten their lifespan. It is also possible that people who 
can afford to go on vacation more frequently have a higher socioeconomic status which is associated 
with better access to healthcare which can increase their lifespan13. The data cannot tell investigators 
what cause and effect are, or through which factors (or mediators) exposure leads to a specific 
outcome, or by which other factors it could be influenced. Sometimes investigators can find plausible 
mechanistic or biologic explanations of exposure as cause for a specific outcome (i.e. causal pathways), 
e.g. bacteria as cause for many diseases. But still, experts may fail in the attempt to completely 
understand all underlying factors and base their assumptions on wrong conclusions. For example, 
many experts criticized the hypothesis that smoking causes cancer and is an important confounder in 
cancer research14. Hence, even when mechanistic explanations are absent, a strong practical effect 
may still be found. For instance, without understanding why, Ignaz Semmelweis discovered that when 
he washed his hands with chlorine solution before attending a delivery, more women survived giving 
birth15. In a time where bacteria seemed ridiculous fantasy, this practical approach could still establish 
cause and effect and saved many lives15.  
To establish cause and effect, RCTs apply a fundamentally different way than observational studies. 
Instead of trying to statistically control for baseline confounding and risking uneven distributions of 
patient characteristics between groups, RCTs use chance in their design. By randomly allocating 
patients to one treatment or the other, RCTs aim at creating equal groups that only differ in the 
treatment they are intended to receive2 16. All known and unknown confounders should, per chance, 
be divided equally between both groups. If all patients adhered to the protocol, the measured effect 
would then be the true causal (unconfounded) effect of the treatment17. However, perfect adherence 
is unlikely. As with observational studies, cause and effect can be seen in a mechanistic and a practical 
way which may both have important aspects in informing treatment choices18. Those interested in the 
mechanistic pathways may now ask how effective the treatment would be if all patients adhered to it, 
i.e. what is the biological effect. For example, to safely avoid pregnancy, a woman may be more 
interested in the effect of taking the anti-baby pill at the same time daily (full-adherence) than in taking 
it with a delay of some hours (non-adherence). This mechanistic question can be answered with a per 
protocol analysis in which only patients are analyzed that adhered to the treatment protocol. The 
greater the non-adherence in a trial, the greater the analyzed groups may deviate from the originally 
randomized ones and confounding is re-introduced. The reason for this is that those who adhere and 
those who do not may be systematically different, and because adherence may depend on the 
allocated treatment as well. Conducting a per-protocol analysis then faces the same statistical 
challenges as observational studies do19 20. Those interested in a practical approach may ask how 
effective the treatment is in general (e.g. the gynecologist cannot know whether or not the patient will 
actually adhere to taking the anti-baby pill at the same time daily and neither does the patient know 
this upfront despite her motivation). The practical question is best answered with an intention-to-treat 
analysis, in which all patients are analyzed according to the groups they were randomly assigned to18. 
The intention-to-treat effect remains unbiased, even if confounding occurs after randomization such 
as high drop-out rates or treatment switches (i.e. post-randomization confounding)19. For example, a 
physical therapist wants to know if a demanding workout will help patients lose weight compared to a 
light workout. Because the interventional workout is too demanding, many patients stop working out 
(drop out) or switch to the light workout. The per-protocol effect may find that the demanding workout 
resulted in higher weight reduction. However, this effect may be confounded by known and unknown 
factors: those who adhered to the demanding workout may have had a different body mass index at 
baseline (this could be statistically controlled for). Their life-situation may have better allowed them 
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to do the workout regularly (this is less likely to be measured in a trial; factors could be number of 
people in the household, previous experience with physical programs, motivation, working hours) and 
also unconscious psychological factors that are not measured or measurable at all may have played a 
role. Even if all these factors had been known, they would also had to have been adequately measured 
and then correctly implemented in the model. The unbiased ITT effect, analyzing all patients according 
to the groups they were allocated to, may not detect a difference between the results of the two 
interventions. While this does not mean that there is no mechanistic difference between the two 
interventions21, it is likely that the less demanding workout would result in a larger average effect than 
the (in theory) stronger but more demanding workout that only a minority will adhere to. The physical 
therapist may in future think twice about which patients could benefit from a demanding workout.  
Confounding can get even more complex when it varies over time in a longitudinal study. A time-
varying confounder is an intermediate variable, i.e. the confounding variable is influenced by previous 
exposure or changes of the exposure over time. While adjusting for baseline confounders (e.g. 
prognostic factors that do not change over time, such as sex) reduces bias, adjusting for time-varying 
confounders may introduce bias when using standard statistical methods22. Conventional per-protocol 
and other standard analyses cannot address this adequately23. Marginal structural models (MSMs), a 
new class of model, can be used to control for time-varying variables and to make causal 
interpretations24 25. They model an alternative scenario, e.g. what would have happened had a patient 
not taken the treatment but the placebo25 26. MSMs are “marginal” because within this framework, the 
patient population is re-weighted in such way that possible outcomes are independent of possible 
confounders. For example, if 50 patients receive treatment A and 50 patients receive treatment B, the 
patients are re-weighted so that each group has 100 patients. This simulates the alternative scenario 
of what would have happened had the patients who received treatment A actually received treatment 
B and vice versa. MSMs are “structural” because they attempt to measure a causal effect. To make 
valid inferences, three main assumptions need to be met: exchangeability, consistency, and 
positivity26-28: Exchangeability means that the groups need to be exchangeable, i.e. there should be no 
unmeasured confounding (i.e. they are “comparable”). Ideally, this would be the case for the baseline 
groups of an RCT with perfect randomization and an infinitive large sample. Consistency requires that 
the exposure is so well defined that variants of it will all lead to the same effect on the outcome. For 
example, when taking a specific dose of diclofenac for pain relief, there must be no difference in 
treatment effect when using the products of different pharmaceutical companies. Positivity means 
that it should be possible for every patient to receive either treatment. For example, positivity is not 
given if patients are included in the study dataset with an absolute contraindication against the study 
drug. Overall, MSM is a complex method to plan, conduct, and report but it may give insightful 
perspectives for study interpretation. 
 
Aims 
Confounding is the connecting theme of all projects in this thesis. It may have far-reaching 
consequences for clinical decision-making29 30. Our overall aim was to improve health care decision 
making by identifying factors that may strengthen or weaken the confidence in evidence used for 
health care decision-making, and by providing empirical guidance on the utility of MSMs. To achieve 
this goal, we applied several meta-epidemiological approaches. By using the framework of systematic 
reviews and meta-analyses, meta-epidemiological research explores the impact of specific study 
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characteristics on treatment effects and the underlying factors of epidemiological and medical 
research as a special form of research on research (or meta-research)3 31. 
 
Objectives  
The first doctoral project had the objective to assess whether authors of observational epidemiologic 
studies considered confounding bias when interpreting their findings. We used a random sample of 
120 cohort or case-control studies reporting any exposure-outcome association. The studies were 
published between 2011 and 2012 by general medical, epidemiological, and specialty journals with the 
highest impact factors. We evaluated whether the consideration of confounding depended on specific 
factors, specifically journal types, study types, exposures, journal impact factor and article annual 
citation rate. 
The second doctoral project had the objective to evaluate the agreement between estimated 
treatment effects of non-randomized studies using causal modelling with marginal structural models 
and RCTs on the same clinical question. We first included any non-randomized healthcare study that 
provided an effect from causal modelling with MSM. Then we searched and included RCTs on the same 
clinical question. In a comparison of the two study designs, we evaluated the direction of treatment 
effects, effect sizes, and confidence intervals for primary effectiveness outcomes, and the overall 
absolute deviation. We determined if the effects of the experimental treatment were more or less 
favorable in non-randomized studies and how the results changed when more RCT evidence was 
published before the respective non-randomized study.  
Intrigued by the emerging use of MSM in RCTs, the third PhD project was a meta-epidemiological 
analysis with focus on marginal structural models in RCTs. The first objective was to systematically 
identify and describe situations where MSM had been used to (re-)analyze results from randomized 
comparisons of medical interventions. Considering all reported results for all available analysis 
methods within each eligible RCT (e.g. MSM, intention-to-treat, per protocol, as treated), the second 
objective was to assess the vibration of all effects32 and the relationship between results of MSM- and 
intention-to-treat-based analyses. 
 
 
Figure 1 Confounded effect of chemotherapy on overall survival through cancer stage 
The arrows denote the proposed causal pathway, i.e. chemotherapy influences the chances of survival in cancer patients, 
cancer stage influences both chemotherapy and survival and thus confounds the effects of chemotherapy on survival. 
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Doctoral Manuscripts 
 
  
  6 
I “Interpretation of epidemiologic studies very often lacked adequate 
consideration of confounding” 
Hemkens LG, Ewald H, Naudet F, Ladanie A, Shaw JG, Sajeev G, Ioannidis JPA. Interpretation of 
epidemiologic studies very often lacked adequate consideration of confounding. Journal of Clinical 
Epidemiology. 2018;93:94-102. 
 
Status 
The manuscript was published in the Journal of Clinical Epidemiology in 2017 ahead of print33 and 
finally in January 201834. 
 
Abstract 
Background and Objective 
Confounding bias is a most pervasive threat to validity of observational epidemiologic research. We 
assessed whether authors of observational epidemiologic studies consider confounding bias when 
interpreting the findings. 
Study Design and Setting 
We randomly selected 120 cohort or case–control studies published in 2011 and 2012 by the general 
medical, epidemiologic, and specialty journals with the highest impact factors. We used Web of 
Science to assess citation metrics through January 2017. 
Results 
Sixty-eight studies (56.7%, 95% confidence interval: 47.8–65.5%) mentioned “confounding” in the 
Abstract or Discussion sections, another 20 (16.7%; 10.0–23.3%) alluded to it, and there was no 
mention or allusion at all in 32 studies (26.7%; 18.8–34.6%). Authors often acknowledged that for 
specific confounders, there was no adjustment (34 studies; 28.3%) or deem it possible or likely that 
confounding affected their main findings (29 studies; 24.2%). However, only two studies (1.7%; 0–
4.0%) specifically used the words “caution” or “cautious” for the interpretation because of 
confounding-related reasons and eventually only four studies (3.3%; 0.1–6.5%) had limitations related 
to confounding or any other bias in their Conclusions. Studies mentioning that the findings were 
possibly or likely affected by confounding were more frequently cited than studies with a statement 
that findings were unlikely affected (median 6.3 vs. 4.0 citations per year, P = 0.04). 
Conclusions 
Many observational studies lack satisfactory discussion of confounding bias. Even when confounding 
bias is mentioned, authors are typically confident that it is rather irrelevant to their findings and they 
rarely call for cautious interpretation. More careful acknowledgment of possible impact of 
confounding is not associated with lower citation impact. 
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What is new? 
Key findings 
- Many highest impact observational studies lack any discussion of confounding bias. Even when 
mentioned, authors are typically confident that it is rather irrelevant for their findings and they 
rarely call for cautious interpretation. 
What this adds to what was known? 
- There is no evidence that acknowledging the potential impact of confounding diminishes 
citation impact of epidemiological studies. 
What is the implication and what should change now? 
- There is a need to encourage researchers and to sensitize reviewers and editors to discuss and 
communicate study limitations introduced by confounding.  
  8 
Introduction 
A confounder may create spurious associations between an exposure and an outcome observed in 
epidemiologic studies [1]. For example, many more people drinking coffee have lung cancer than 
people not drinking coffee, but this is because they more often smoke [2]. Many confounders are 
difficult to pinpoint with certainty, many are entirely unknown, and many others are known, but are 
still not measured and thus cannot be considered in the analysis of epidemiologic studies. 
Understanding confounding and separating it from causal effects can be very difficult. For example, 
even smoking's causal role in cancer, and its potential to confound other observed associations in 
cancer studies, was not clear across many years of early epidemiologic research [3]. Bias caused by 
unknown confounders is directly addressable only by randomization, and thus, confounding bias can 
never be entirely ruled out in nonrandomized studies. Consequently, in the most widely applied 
framework to assess quality of evidence for healthcare decisions (GRADE), evidence from 
observational research is initially considered low quality [4]. 
Because bias due to confounding is a core limitation of observational research, numerous 
recommendations and statements call for a careful consideration when reporting, discussing, and 
making conclusions from observational research [[5], [6], [7], [8], [9], [10]]. For example, the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement, the most 
widely endorsed guideline for reporting of observational research, prominently emphasizes the 
discussion of confounding and explicitly states “It is important not only to identify the sources of bias 
and confounding that could have affected results, but also to discuss the relative importance of 
different biases, including the likely direction and magnitude of any potential bias” and “due 
consideration should be given to confounding […]. Authors should also consider residual confounding 
due to unmeasured variables or imprecise measurement of confounders” [6]. 
Despite these recommendations, many investigators might feel that acknowledgment of confounding 
will cast doubts on their findings. They might prefer to either be silent about this possibility or explicitly 
discredit the possibility that confounding may have affected their conclusions. Important questions 
can be asked: Do authors of epidemiologic studies published in major journals acknowledge 
confounding properly and sufficiently? Does more explicit acknowledgment of confounding as a 
limitation decrease the subsequent citation impact of their work? To address these questions, here we 
conducted a meta-epidemiologic survey of observational studies published in high-impact journals. 
Our primary aim was to assess whether authors of observational epidemiologic studies consider 
confounding bias when interpreting the findings in the Discussion sections and concluding statements 
of their articles. Our secondary aim was to determine whether such explicit discussion is associated 
with lower citation impact. 
 
Methods 
Data identification and eligibility 
We selected 24 journals with the highest impact factors (Journal Citation Reports 2010): The top eight 
from the “medicine, general, and internal” category [New England Journal of Medicine, Lancet, JAMA, 
Annals of Internal Medicine, PLOS Medicine, BMJ, Archives of Internal Medicine (currently JAMA 
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Internal Medicine), CMAJ], the top eight from the “public, occupational, and environmental health” 
category (Environmental Health, Epidemiology, International Journal of Epidemiology, American 
Journal of Epidemiology, Bulletin of the World Health Organization, American Journal of Preventive 
Medicine, European Journal of Epidemiology, Genetic Epidemiology), and the journal with highest 
impact factor in each of eight “medical specialty” sub-categories (cardiology and cardiovascular 
disease, gastroenterology, obstetrics and gynecology, oncology, pediatrics, rheumatology, surgery, 
urology and nephrology; i.e., Circulation, Gastroenterology, Obstetrics, and Gynecology, Journal of 
Clinical Oncology, Pediatrics, Annals of Rheumatic Diseases, Annals of Surgery, Journal of the American 
Society of Nephrology). We did not consider journals focusing exclusively on reviews (e.g., 
Epidemiologic Reviews) or on basic and/or preclinical research (e.g., Cancer Cell). 
We searched MEDLINE for cohort and case–control studies published in these journals in 2011 and 
2012 (last search on December 4, 2015; details in Webappendix 1). 
The articles retrieved were stratified by journal category. Two independent reviewers (H.E. and F.N.) 
evaluated randomly selected articles for eligibility until they identified 120 eligible articles (20 per 
journal type and year; which would allow for standard deviation of <4% for estimated proportions of 
75% or 25%). The study flow is shown in Webappendix 2. We included any study clearly described as 
“cohort study” or “case–control study” (explicitly using these terms) and reporting any exposure–
outcome association and thus being theoretically prone to confounding bias. No further eligibility 
criteria were applied. Any disagreements were resolved by discussion or with a third reviewer (L.G.H.). 
The random sample included studies published in 22 of the 24 eligible journals (exceptions were 
Bulletin of the World Health Organization and Genetic Epidemiology), and each journal contributed a 
median of four studies [interquartile range (IQR) 2–6]. 
Data extraction 
Two independent reviewers (two of L.G.H., H.E., F.N.) extracted the reported study design (i.e., case–
control, prospective, retrospective, or unclassified cohort study or nested case–control study; we 
applied these specific terms to categorize the study design as self-reported by the authors) and 
categorized the area of research for all pertinent articles. Any disagreements were resolved by 
discussion or with the third reviewer (L.G.H., H.E., or F.N.). 
In addition to manual extractions, two independent reviewers (L.G.H. and H.E.) searched all full-texts 
automatically (using PDF viewer software) for terms related to propensity scores or marginal structural 
models anywhere in the articles and they assessed if propensity score–based methods or marginal 
structural models were used in the studies. There was perfect agreement (100%) between reviewers. 
One reviewer (L.G.H.) extracted from Web of Knowledge bibliographic data, specifically the journal's 
2010 impact factor and how often the study was cited (Web of Science Core Collection) through 
January 2, 2017, to calculate an annual citation rate (total citations received per years elapsed since 
publication). 
Evaluation of confounding statements and bias consideration 
We systematically evaluated the consideration of confounding bias in the Abstract and Discussion 
sections of included studies using six standardized prespecified questions (Table 1). We focused on the 
Abstract and Discussion because these are the sections readers typically focus on the most and from 
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which they are most likely to draw bottom line conclusions on what the research means and what 
caveats might exist. We did not evaluate the Introduction, Methods, or Results sections of the 
publications. 
First, we evaluated if the term “confounding” in any form is mentioned at all, regardless of whether it 
is actually used to discuss the findings of the study or not. We specifically screened Abstract and 
Discussion sections of the articles for the term “confounding” or variations thereof (Question 1). We 
also captured any allusions or statements referring to the concept of confounding bias without 
explicitly using such terms. We also specifically screened the articles for the term “bias” (Question 2) 
and explicitly perused any mentions of bias for possible relations to confounding. Details with 
examples are shown in Table 1. 
Second, we evaluated if the authors explicitly mention specific potential confounders that were not 
adjusted for in the analyses (Question 3), or if the authors explicitly discuss whether confounding bias 
is likely, possible, or unlikely to affect their main findings (Question 4). 
Third, we evaluated if confounding bias is considered when interpreting the results or drawing 
conclusions. Specifically, we evaluated if the authors state that their main results need to be 
interpreted with caution due to confounding, using the term “caution,” “cautious,” or variants thereof 
(Question 5). Finally, we specifically screened whether their concluding statements include any 
limitation or uncertainty related to confounding or bias at all (Question 6). This was evaluated in the 
section either headed “conclusion,” “summary,” or similar; if such heading did not exist, we evaluated 
all paragraphs following a concluding statement beginning with, for example, “in conclusion,” or “in 
summary,” or evaluated the last paragraph of the Discussion. 
We developed and pilot tested the operationalization of the questions and iteratively specified the 
wording of the questions to arrive at detailed extraction instructions. Two reviewers (two of L.G.H., 
H.E., F.N., A.L.) then assessed all articles independently (unaware of any extractions in the pilot), 
resolving any disagreements by discussion or with a third reviewer (L.G.H. or H.E.). 
Data analysis 
In addition to an overall description of the study sample and the statements on confounding, we 
analyzed whether the consideration of confounding (Questions 1–6) differed between the journal 
types (general medical vs. epidemiology vs. specialty journal), study types (cohort vs. case–control), 
exposures (modifiable vs. nonmodifiable), and whether it was associated with journal impact factor 
and article annual citation rate. We tested differences between continuous variables with the Mann–
Whitney U test, differences between categorical data with the Fisher's exact test. Results for 
continuous measures are medians with IQRs. All analyses were done with Stata 13.1. P values are two 
tailed. 
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Results 
Evaluated studies 
Of the 120 articles, 90 described cohort studies (75%) and 30 case–control studies (25%; Table 2; 
details in Webappendix 3). Case–control studies were typically published in epidemiologic journals (17 
of 30; 56.7%). The 120 studies covered a wide spectrum of medical areas, and there were differences 
in the areas covered between general medical journals and specialty journals, with pediatrics and 
oncology being more common in the latter. Most studies (74; 61.7%) analyzed effects of exposures 
that cannot practically be investigated in experimental studies as they are either not directly 
modifiable or are harmful (e.g., associations of health outcomes with environmental factors, 
biomarkers, or demographic characteristics). Effects of potentially modifiable exposures (e.g., drugs, 
diets, or surgery) were analyzed in 35 studies (29.2%) and were less common in epidemiologic journals. 
The median impact factor of the 22 journals was 7.9 (IQR, 5.6–13.5) in 2010 and the studies received 
a median of 5.1 (IQR, 2.5–9.2) annual citations, with clear differences depending on journal type. Of 
the 120 studies, only six used propensity score methods and one used marginal structural modeling. 
Mere mentioning of confounding or bias 
Confounding bias was not mentioned or alluded to at all in Abstracts and Discussions of 32 of the 120 
studies (26.7%; 95% confidence interval [CI]: 18.8–34.6%; Table 3); in 20 studies (16.7%; 95% CI: 10.0–
23.3%), there was some allusion to the concept of confounding indirectly without using this specific 
term, and 68 of 120 (56.7%; 95% CI: 47.8–65.5%) mentioned the term “confounding” or some same-
root variant. The term “bias” was used in 72 of the 120 studies (60%; 95% CI: 51.2–68.8%). Twenty-
seven studies (22.5%; 95% CI: 15.0–30.0%) mentioned neither confounding nor bias at all in their 
Abstracts and Discussions. 
Any mention that confounding may affect results 
Among the 68 of 120 studies that used the term “confounding” or related terminology, three (2.5%; 
95% CI: 0–5.3%) said that it is likely that confounding affects their main findings, 26 (21.7%; 95% CI: 
14.3–29.0%) said it is possible, 11 (9.2%; 95% CI: 4.0–14.3%) said it is unlikely, and the remaining 28 
did not comment in this regard. 
Acknowledgment of unmeasured confounders 
Authors of 34 studies (28.3%; 95% CI: 20.3–36.4%) acknowledged that for specific confounders, there 
was no adjustment, and the reason provided in the majority (28 of 34) was that these confounders had 
not been measured. Another eight studies mentioned unmeasured confounding in general without 
specifying the unmeasured confounders. 
Cautious interpretation and limitations in conclusions 
An explicit statement in the Discussion section (or Abstract) that the interpretation of study results 
should be made with caution due to possible confounding was made in only 2 of 120 studies (1.7%; 
95% CI: 0–4.0%). Specifically, in a study of caffeinated beverage and soda consumption and time to 
pregnancy, Hatch et al. clearly stated “We caution that these associations may reflect unmeasured 
confounding by diet or other lifestyle factors” [11]. In a study of the association of different biomarkers 
and risk of type II diabetes, Montonen et al. stated “Caution is needed when interpreting the results of 
the analyses on proportion of the association explained. First, the proportion estimates […] may be 
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biased if there is unmeasured confounding between the biomarkers and the outcome [References]” 
[19]. 
Only 4 of 120 studies (3.3%; 95% CI: 0.1–6.5%) mentioned any limitations related to bias or 
confounding in their Conclusions. 
Of the three studies where the authors' discussion expressed that confounding likely affects their main 
results, this caution was clearly expressed in the Conclusions in one of the three. Such caution was 
conveyed in the Conclusion in only 2 of the 26 studies where the authors mentioned possible 
confounding. 
Of the 42 studies where unmeasured confounders were discussed (specifically or in general terms), 
only one (2.4%) explicitly stated that the interpretation of the results should be made with caution and 
only four (9.5%) expressed in their Conclusions limitations because of confounding or any other bias. 
Overall assessment 
The interrater agreement was very high for all assessed questions, ranging from 86.5% to 99.2%. 
Figure 1 shows the overlap we observed between the different ways of handling and characterizing 
the potential presence and impact of confounding bias. 
Associations with type of journal and impact 
The findings were overall the same across the types of journals (Table 3). None of the evaluated 
aspects of considering confounding bias were associated with journal impact factor or subsequent 
citation impact, with one exception (Table 4). Studies with a statement that the findings were possibly 
or likely affected by confounding bias were more frequently cited than those studies with a statement 
that the findings were unlikely affected (median 6.3 vs. 4.0 citations per year, P = 0.04). We found no 
differences between cohort and case–control studies or between studies evaluating modifiable vs. 
nonmodifiable exposures (data not shown). 
 
Discussion 
Our analysis of 120 randomly selected epidemiologic studies showed that while a narrow majority 
studies do mention confounding bias to some degree, very few acknowledge that it is a reason for 
major caution in interpreting the key findings. More than a quarter of the articles completely ignored 
“confounding” in the Abstract or Discussion sections, and most of them do not even mention the term 
“bias” in general. Despite the frequent presence and even awareness of specific unmeasured 
confounders and the often reported possible impact on the main findings, conclusions are almost 
never made with explicit caution. We found only two cases with explicit statements that cautious 
interpretation is required because of confounding. Interestingly, in one of them, this caution owing to 
unmeasured confounding is immediately diluted in the text by stating “In the present study, we 
included a large variety of known risk factors as well as of biomarkers, thereby minimizing unmeasured 
confounding” [19]. This illustrates the overall impression we gained during our evaluation, that many 
discussions of confounding in these top journals are superficial and appear to be attempts to negate 
the importance and impact of confounding in the published work. 
We found no indications that this phenomenon is limited to certain areas of research, as findings were 
similar across types of journals, their impact factors, and study types and topics. Of note, many of the 
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studies we evaluated were from journals that published the STROBE reporting guidelines in 2007 (i.e., 
Lancet, Epidemiology, Bulletin of the World Health Organization, BMJ, PLOS Medicine, Annals of 
Internal Medicine). The observed association of higher study citation numbers with statements 
acknowledging that confounding bias could exist might be just a chance finding, or be due to 
confounding. Nevertheless, it suggests that statements acknowledging potential methodological 
weaknesses have no negative citation impact. 
Investigators should not worry that their observational study will be discredited if they acknowledge 
(as they should) that their work is subject to confounding that might affect their results. 
Acknowledgment and thorough discussion of the impact of confounding bias may be a marker of 
researchers with more epidemiologic training being involved in the study, who may have better 
institutional access to better, larger datasets, and work in larger research teams, all of which may also 
help explain higher citation rates for articles that explicitly discuss confounding. We did not adjust for 
any of these potentially explanatory variables in our descriptive analyses as we do not aim to make 
any causal inferences. If anything, we observed more citations for articles that acknowledged 
confounding than for those that did not. 
The acknowledgment of unmeasured confounding (in accordance to the STROBE reporting guideline) 
has been systematically assessed in previous empirical work for observational research published in 
five general medicine journals and five epidemiologic journals (most of them included also in our 
analysis) for the years 2004–2007 and 2010–2012 [[22], [23]]. Comments on the likelihood of 
unmeasured confounding were present in 59–85% of the studies, but only 16–32% gave any qualitative 
statement about the impact on the findings, which agrees well with our overall study results. However, 
both of these previous empirical studies narrowly evaluated observational research specifically 
focusing on medical interventions, while we examined the broader landscape of observational 
investigation within the medical literature, only the minority of which pertained to interventions. 
Some limitations of our work deserve closer attention. First, we analyzed only a small sample of the 
observational study literature. Perhaps, a larger sample may have allowed us to detect small 
differences between journal types or other factors affecting the consideration of confounding. 
However, large differences are unlikely to have been missed. 
Second, we evaluated studies that were published 4 and 5 years ago, which was necessary for a 
meaningful analysis of subsequent citation impact. Previous evaluations have found that the 
introduction of STROBE in 2007, arguably the most influential effort to improve reporting quality, has 
had only modest impact on reporting quality [[22], [23]]. No new major similar efforts have been 
launched in the last 5 years; therefore, we have no reason to believe that reporting of observational 
research would have changed substantially in the last few years. 
Third, by only looking at 24 high-impact journals, it is uncertain if our findings are generalizable to the 
rest of the medical literature. It is quite possible that we may even underestimate the extent to which 
implications of confounding bias go unaddressed in the medical literature. 
We also acknowledge that confounding bias might be seen by some researchers as an inevitable 
limitation of observational studies that is too well-known to merit discussion. However, as causal 
interpretations depend on the validity of the implicit assumption of no unmeasured/residual 
confounding, the implications of bias due to failure of this assumption should be considered. Dealing 
with confounding bias, understanding its impact (e.g., through qualitative discussion of the magnitude 
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and direction of bias and more quantitative sensitivity analyses [[24], [25]]), minimizing its influence, 
and acknowledging the residual uncertainty is an integral core for inference-making in epidemiology. 
In some situations, authors might not be much interested in causality and expressions about cautious 
interpretation, for example, when they explore associations for developing diagnostic rules. However, 
only very few studies in our sample addressed such topics. 
Underreporting of limitations may exaggerate conclusions and could sometimes be perceived as 
sensationalism, overall diminishing trust in research. We found no evidence that considering the 
possibility of confounding bias diminishes citation impact. This agrees also with recent evaluations of 
press releases of observational studies showing that cautious interpretations and wide media coverage 
are well compatible [[26], [27]]. This is reassuring for researchers and may encourage them to discuss 
and communicate any limitation introduced by confounders in a thorough and determined way and 
“not take them as mythical or uncontrollable phantoms that destroy studies” [28]. 
Overall, we believe that there is a need to encourage researchers to report more careful and 
determined considerations of confounding bias and to encourage peer-reviewers, journal editors, and 
research funders to appreciate this. Many of the journals we analyzed have published the STROBE 
guideline, and some explicitly refer to them in their Instructions for Authors. Recently, PLOS Medicine 
intensified the requirements for authors of observational studies, asking that they “must complete the 
appropriate reporting checklist not only with page references, but also with sufficient text excerpted 
from the manuscript to explain how they accomplished all applicable items” [29]. Our results 
demonstrate that such activities are well justified. Given that not much has improved over many years, 
facing the tsunami of big datasets with all their promises, limitations, and risks of spurious findings 
[30], we believe that more concerted action is needed to improve the appropriate discussion of 
epidemiologic findings. 
 
Conclusion 
Confounding bias is a pervasive threat to the validity of observational epidemiologic research. 
Inadequate consideration and lack of discussion of implications of confounding bias are very frequent 
among the highest impact observational studies. Despite reasonable cause for careful discussion and 
cautious interpretation, authors often convey confidence, without cause or supporting evidence, that 
confounding bias is largely irrelevant for their findings. We think that such confidence is not justified. 
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Tables 
 
Table 1: Assessment of consideration of confounding bias in Abstracts and Discussions 
1. Do the authors mention confounding using explicitly the terms “confounder(s),” 
“confounding,” “confound,” or do they allude to it without using those terms, or is 
confounding not considered at all? 
 
Examples for “yes”: 
 
“We caution that these associations may reflect unmeasured confounding by diet or other 
lifestyle factors” [11]. 
 
Example for “alluded”: 
 
“Another potential limitation is our inability to control for age at menopause among women 
having a hysterectomy before natural menopause; for these women, age at menopause is 
unknown” [12]. 
 
“When we included the characteristics we could define in multivariable models the 
association of arm injection site with a significantly higher risk of medically attended local 
reactions persisted, but it is possible that bias may have influenced the findings” [13]. 
 
2.  Do the authors mention bias using explicitly the term “bias”? 
 
Example for “yes”: 
 
“Where available, we relied on HIV diagnosis based on clinical features, which may be subject 
to biases in assessing the factors contributing to diarrheal disease among participants since 
HIV infection at early stages may have been missed and not all data were routinely captured” 
[14]. 
 
3. Do the authors mention specific confounders that have not been adjusted for? 
 
(If yes, what were the reasons? If not, were there unspecified unmeasured confounders 
without specifically stating which ones?) 
 
Example for “yes”: 
 
“We were unable to adjust for additional confounding variables with a known association 
with mortality (for example, blood glucose and postarrest pH) that were not collected as part 
of the PICANet data set” [15]. 
 
4. Do the authors state that their main findings are likely, possibly, or unlikely affected by 
residual confounding? 
 
Example for “yes, likely”: 
 
“Therefore, some residual confounding with parental psychopathology seems likely” [16]. 
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Example for “yes, possibly”: 
 
“However, although we adjusted for severity of the initial diagnosis of depression, we could 
use only a crude measure as we did not have a validated depression severity score. We 
cannot therefore exclude the possible effect of residual confounding on our results” [17]. 
 
Example for “yes, unlikely”: 
 
“Minimal differences were observed between the crude and adjusted odds ratios for the 
exposure variable, suggesting that SEIFA and ethnicity were unlikely to be major confounders 
in this analysis” [18]. 
 
5. Do the authors state that their main findings need to be interpreted with caution due to 
confounding? 
 
We answered this question with “yes” in cases with a clear statement that cautious 
interpretation is required because of confounding. 
 
Example for “yes”: 
 
“Caution is needed when interpreting the results of the analyses on proportion of the 
association explained. First, the proportion estimates, decomposed from the total effect by 
adjusting for other biomarkers, may be biased if there is unmeasured confounding between 
the biomarkers and the outcome [Reference]. In the present study, we included a large 
variety of known risk factors as well as of biomarkers, thereby minimizing unmeasured 
confounding” [19]. 
 
6. Do the authors call for caution or indicate limitations or uncertainty due to possible 
confounding or other bias in their conclusions? 
 
Example for “yes”: 
 
“We caution that these associations may reflect unmeasured confounding by diet or other 
lifestyle factors” [11]. 
 
“Given the small sample size, however, the potentially confounding effects of maternal IQ 
cannot be excluded and should be evaluated in a larger study” [20]. 
 
“In summary, notwithstanding the possibility of residual selection bias, patients who […]” 
[21]. 
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Table 2: Characteristics of studies 
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Table 3: Statements on confounding 
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Table 4: Citation impact 
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Figures 
 
 
Figure 1: Venn diagram on different aspects of consideration of confounding bias in discussions of 
epidemiologic research. Each ellipsoid area corresponds to one aspect of consideration of confounding 
bias. The numbers indicate the number of studies sharing the characteristics in the overlapping areas, 
for example, there are 14 epidemiologic studies (12% of 120) in which “confounding” is mentioned in 
the Abstract or Discussion, the authors deem the main findings possibly or likely affected by 
confounding, and nonadjusted confounders are acknowledged, but there are no limitations in the 
Conclusions related to confounding or any bias. Fifty-two studies are not covered by any of the areas. 
The percentages do not correspond to the size of circular areas. 
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Webappendix 
Supplementary data related to this article can be found at 
https://doi.org/10.1016/j.jclinepi.2017.09.013. 
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II “Impact of Marginal Structural Models as enhanced confounder 
control methods in non-randomized comparative effectiveness: a meta-
epidemiologic study” 
Ewald H, Ioannidis JPA, Ladanie A, Mc Cord K, Bucher HC, Hemkens LG 
 
Status 
The manuscript was under peer review by the BMJ but not considered for publication. We plan to 
submit it to another high-impact journal in April 2018. 
 
Abstract 
Objectives 
To evaluate the agreement of estimated treatment effects between non-randomized studies using 
causal modelling (with marginal structural models) and randomized controlled trials (RCTs) on the 
same clinical question. 
Design 
Meta-epidemiological study. 
Data sources 
PubMed, Scopus and citations of key references searched up to April 2017. 
Methods 
Any non-randomized study using marginal structural models for causal modelling providing an effect 
estimate on any healthcare outcome of any treatment was eligible. We systematically sought RCTs on 
the same clinical question and compared the direction of treatment effects, effect sizes, and 
confidence intervals for primary effectiveness outcomes between study designs. We evaluated the 
overall absolute deviation between study designs and we assessed if non-randomized studies found 
more or less favorable effects for the experimental treatment. We used the ratio of odds ratios (ROR; 
the summary odds ratio of trials divided by the reported estimate from non-randomized studies) for 
each clinical question and then combined the RORs using random-effects meta-analysis. Meta-
regression was used to assess whether the agreement between study designs is associated with 
previous knowledge of RCT-effects. 
Results  
The main analysis included 19 non-randomized studies with 1039570 patients and 141 RCTs with 
120669 patients. Non-randomized studies indicated treatment effect estimates in the opposite 
direction from RCTs for 8 clinical questions (42%), and their 95% confidence interval did not include 
the RCT estimate in 9 clinical questions (47%). The effect estimates deviated systematically by 1.29-
fold (summary absolute deviation OR 1.29; 95% confidence interval 1.12 to 1.48). Overall, causal 
modelling studies tended to show more favorable results for the experimental treatment (summary 
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ROR 1.14; 95% confidence interval 0.93 to 1.41), in particular when they clearly focused on healthcare 
decision making and clinical interpretation not on statistical methodology (16 studies, summary ROR 
1.34; 95% confidence interval 1.03 to 1.75), and when more RCT evidence was previously available 
(p=0.037). 
Conclusions 
Non-randomized studies using causal modelling with marginal structural models may give different 
answers than RCTs evaluating the same clinical question. Caution continues to be required when non-
randomized “real world” evidence is used to guide health care decisions. 
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What is known on this topic: 
- Many health care stakeholders call for use of non-randomized “real world” evidence for 
decision-making  
- Non-randomized studies are prone to bias due to confounding  
- Causal modelling with marginal structural models may theoretically overcome such biases 
under the critical assumption that all confounders are known, correctly measured, and 
precisely included in the models 
 
What does it add: 
- Non-randomized “real world” studies using causal modelling may give different answers than 
randomized controlled trials with effects that typically deviate and sometimes show stronger 
benefits of experimental treatments  
- Caution remains crucial when non-randomized evidence is used to guide health care decisions 
– even when causal modelling techniques were applied and especially when no evidence from 
randomized controlled trials exists 
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Introduction 
Randomized controlled trials (RCTs) are able to determine the causal effects of choosing between two 
or more treatment options for an intervention.1 2 However, RCTs are not available for many important 
healthcare questions. Since healthcare decision makers then have to rely on non-randomized 
observational studies as the only evidence, attempts are made to increase the reliability of these 
studies.2 3 To assess the causal effect of a treatment choice, it would be inadequate to simply compare 
outcomes between patients selecting different treatments. The reason is that in the “real world”, the 
choice is not random. It often depends on specific factors, such as comorbidities or personal values 
and preferences of patients and care providers, that are also associated with future health outcomes 
(confounding by indication). Many health care stakeholders call for use of non-randomized “real 
world” evidence and its evaluation in the context of health care decision-making – even for drug 
approval as in recent US legislation.4-7 Although only randomization can directly eliminate confounding, 
several methods are used in observational studies in the attempt to address this issue, for example 
multivariate regression analysis or methods using propensity score.8 9  
We have recently shown that studies based on routinely collected health data analyzed with 
propensity score methods may substantially overestimate treatment benefits and may provide very 
different answers than RCTs on the same clinical question.10 However, these methods balance 
confounders at baseline without addressing confounders arising during follow-up when patients 
switch or stop treatments because of unsatisfactory results.11 Novel approaches have been proposed 
aiming to eliminate this time-dependent confounding and to measure causal effects of treatments in 
such situations.12 The most frequently used method involves marginal structural models (MSM). MSMs 
are a relatively new class of statistical models that are increasingly applied for causal inference in non-
randomized studies over the last two decades.11 13 14 The underlying essential inherent limitation of all 
non-randomized study designs remains the same,15 that is the assumption that all relevant 
confounders are known, measured, and correctly integrated in the analyses.  
There is no meta-epidemiologic analysis evaluating if non-randomized “real world” evidence using 
causal modelling with MSM 16 can reliably estimate effects as found in RCTs, which would be a 
prerequisite for reliably using this evidence for healthcare decision-making. We aimed to evaluate the 
agreement of treatment effects estimated by non-randomized studies using MSM for causal modelling 
with effects of RCTs investigating the same clinical question in a comprehensive meta-epidemiological 
study. 
 
Methods 
We analyzed non-randomized studies that evaluated any healthcare intervention with causal 
modelling using MSM (MSM-studies). We systematically compared the findings from such studies for 
various clinical questions with the findings from RCTs on the same clinical question. 
Identification of non-randomized studies using marginal structural models 
We included any observational, non-randomized study that (1) provided at least one effect estimate 
of any binary health outcome clearly based on the use of MSM, (2) mentioned the intervention, the 
evaluated population, and any result (not necessarily MSM-based) in the abstract, (3) investigated a 
clearly defined treatment and comparator . We applied no language restrictions. 
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We screened the bibliography and citations of 12 key references11 13 16-25 on MSM using Web of Science 
(last search 23 June 2014) to identify relevant MSM-studies. We then used the search results for the 
development of a PubMed search strategy (including terms related to “marginal structural models”; 
last search 15 October 2014; Webappendix) to identify further pertinent articles. Two reviewers (HE, 
LGH) independently screened all titles, abstracts and full-texts, and solved any disagreement through 
discussion. 
One reviewer (HE) then identified the clinical questions (following the PICO scheme26, i.e. the 
composite of population, intervention, comparison, and outcome) addressed in each eligible MSM-
study and a second reviewer (LGH) verified this. 
Identification of corresponding randomized trial evidence 
First, we searched for systematic reviews that reported treatment effects of RCTs that assessed the 
same clinical question as the MSM-study. One reviewer (HE) developed search strategies for all clinical 
questions using a standardized search building approach and applying standard filters for systematic 
reviews and meta-analyses.27 Potentially relevant RCTs cited in the MSM-study were used as 
benchmark to maximize the sensitivity of the search, i.e. we adapted the search until we retrieved all 
these potentially relevant studies. All search strategies were checked by a second reviewer (LGH). One 
reviewer (HE) then searched PubMed (last search 21 April 2016), screened all titles, abstracts, and full-
texts. She recorded any article that she deemed possibly eligible; another reviewer (LGH) verified 
eligibility of all included or possibly relevant studies (LGH). Another reviewer evaluated a random 10% 
sample of all clinical questions that were not deemed included or possibly relevant (LGH or AL). The 
interrater agreement was perfect (100%). 
Second, we hand-searched the reference lists of eligible MSM-study publications for any mentioned 
or cited RCTs on the same clinical question.  
Third, we screened all studies citing eligible MSM-study publications for eligible RCTs using SCOPUS 
(last search 28 March 2017). 
Fourth, whenever we found eligible RCTs that were not covered by a systematic review discovered in 
the first step (this was the case for 3 clinical questions), we updated our search for systematic reviews 
and also did a complete search on PubMed for RCTs on that clinical question using the PubMed 
standard filter for RCTs (last search 12 April 2017).  
One reviewer (HE) screened all reference lists, titles and abstracts. All potentially relevant full-texts 
were independently screened by two reviewers (HE, LGH) who solved any disagreement through 
discussion. 
Data Extraction  
From each MSM-study, we extracted each clinical question with corresponding MSM-based treatment 
effect. We extracted RCT-based treatment effects from available systematic reviews of RCTs (we used 
individual trial results if available for all but three clinical questions28-30 where we extracted the 
summary effect estimates with confidence intervals from meta-analyses in the systematic review). We 
used RCT publications when there was no systematic review. Information on the conduct of intention-
to-treat analyses, the number of patients missing (i.e. lost-to-follow-up, withdrawn, discontinued or 
dropped out), and the number of patients who switched their allocated treatment were extracted from 
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RCT publications. For information on risk of bias of the RCTs, we extracted the assessments from 
available systematic reviews, otherwise we used the original RCT data applying Cochrane standards.27 
We asked systematic review authors for bibliographic information if it was not clear to us which RCTs 
were included in their meta-analyses. One reviewer extracted and assessed all data (HE) and another 
verified them (KM).  
Statistical analysis 
For the consistent reflection of treatment effects across all clinical questions from the MSM-studies 
and RCTs, we inverted the effect estimates and confidence intervals where necessary so that the 
results represent effects of experimental treatments versus control treatments for an unfavorable 
outcome. The first treatment comparator always reflects the experimental group (i.e. newer, less 
established, treatment of interest) and the second comparator the control group (i.e. standard of care, 
placebo, older treatment). Where this classification was not clear, we consulted experts in the field. 
Whenever the outcome was favorable, we inverted the reported study effect to reflect the 
complementary unfavorable outcome (e.g. death instead of survival). For the RCTs, we used the same 
outcome and direction of comparison as we had used in the MSM-studies. 
When an MSM-study evaluated several outcomes for the same treatment comparison in the same 
population, we selected the (all-cause) mortality outcome for the main analysis because mortality is 
of high relevance for decision makers, rather unambiguously measured, and probably less prone to 
data accuracy problems in routinely collected data sources (mortality was the primary endpoint in 2 of 
3 MSM-studies that were concerned31 32). When there were multiple effect estimates reported for the 
same outcome (i.e. different results for one clinical question, derived from various MSMs), we used 
the effect estimate mentioned first. 
We assumed that reported relative risks or hazard ratios in MSM-studies are close approximations of 
ORs (which is reasonable when the event rate is low,33 as was in our sample with a median event rate 
of the intervention and control groups of 5.5%, IQR 1% to 12%). 
Treatment effects of multiple RCTs on the same clinical question were combined to obtain one 
summary OR per clinical question with random effects model meta-analyses using the DerSimonian 
and Laird method. 
First, we examined how often MSM-studies and RCTs differed in the direction of the point estimates; 
how often the MSM-study and the respective RCTs had the same direction in the presence of statistical 
significance (their 95% confidence intervals excluded the null effect); how often the RCTs’ summary 
estimate was not included in the 95% confidence interval of the respective MSM-study; and how often 
the treatment effects from MSM-studies and RCTs differed beyond chance.  
Second, we quantified the absolute deviation between OR estimates from MSM-studies and estimates 
from corresponding RCTs for each clinical question (calculated as absolute difference between the 
RCT-based and MSM-based log(OR)s and back transformed on the OR-scale). This provides an estimate 
of deviation between study designs independent from assumptions about effect directions, 
experimental and control treatments. The absolute deviation estimate and the confidence interval 
limits are positive by definition and reported as x-fold deviation on the OR scale. For example, the 
absolute deviation would be 1.25-fold when one study design finds an OR = 1 and the other design 
finds an OR = 0.8 or an OR = 1.25. 
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Third, we assessed the directions of deviations to explore if effects found in MSM-studies for 
experimental treatments would be more or less favorable than in RCTs. For this, we used the ratio of 
odds ratio (ROR) approach, i.e. the division of the summary OR of RCTs by the MSM-based treatment 
effect (after log-transformation).34 A ROR for experimental treatment effects above 1 indicates that 
the MSM-study measured a more favorable result of the experimental treatment benefit than the 
RCTs, a ROR below 1 indicates less favorable treatment benefits found in MSM-studies. 
The absolute deviation ORs and the RORs for experimental treatment effects of all clinical questions 
were each synthesized with random effects models (DerSimonian and Laird) to obtain overarching 
summaries of the relationship of effects in non-randomized studies using causal modelling versus 
corresponding randomized trial evidence.  
Fourth, we explored if there were indications to assume that results of MSM-studies would be different 
when they are done without pre-existing randomized evidence on treatment effects35. Because almost 
all clinical questions in our analysis had pre-existing randomized evidence when the causal model 
results were published, we could not apply the cleanest approach by including only MSM-studies 
without pre-existing trials.35 Instead we conducted a meta-regression in which we estimated the 
association between the ROR per clinical question and the amount of randomized evidence available 
at the time of the publication of the MSM-study. The amount of evidence was expressed by the inverse 
of the variance (i.e. by the weight in the random-effects meta-analysis of all the RCTs with publication 
dates before the MSM-study). We also conducted sensitivity analyses excluding all RCTs with a 
publication date before the MSM-study or excluding all RCTs published after the MSM-study.  
We conducted further sensitivity analyses (whenever data were available on at least 5 clinical 
questions) excluding 3 MSM-studies focusing on statistical methodology of causal modelling without 
having any clinical interpretations for healthcare decision making in their conclusions16 36 37; including 
only all-cause mortality effects; including only non-mortality effects (here, in case of several pertinent 
estimates, we selected the most precise one, i.e. the one with smallest confidence interval); excluding 
clinical questions with active treatment controls; excluding clinical questions without active treatment 
controls; excluding RCTs with either high risk of bias in any of the bias domains, and/or missing data of 
more than 10%, and/or where more than 10% of the patients switched their allocated treatment; and 
using a fixed-effect model to combine data from RCTs. 
We used Stata 14.2 (Stata Corp, College Station, TX, USA) for all analyses. We used the ‘metan’-
command for meta-analyses, the “metareg”-command for meta-regression, and the ‘heterogi’-
command for the confidence intervals of I2 38. P-values are two tailed. 
Patient involvement 
No patients were involved in this research. 
 
Results 
Studies evaluated 
The literature search for MSM-studies resulted in 3916 references; we screened titles and abstracts 
and obtained 646 articles in full-text. We found 98 eligible articles on causal modelling studies using 
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MSM. In search for corresponding RCT-evidence, we screened 9926 references. Overall, we found 168 
RCTs corresponding to 25 clinical questions addressed in 19 of the 98 MSM-studies (Figure 1, Table 1). 
Three of the 19 MSM-studies31 32 39 evaluated more than one clinical question, i.e. they assessed several 
outcomes (all including all-cause mortality which we used for the main analysis) in the same population 
and treatment comparison (Table 1). Of the 19 MSM-studies included in the main analysis, 14 (76%) 
had all-cause mortality as outcome. Most MSM-studies were related to HIV (6/19, 32%) or nephrology 
(8/19, 42%) and explored drug treatment comparisons (15/19, 79%). This was similar to the topics in 
all identified MSM-studies (HIV 43/98, 44%; nephrology 19/98, 19%; 52/98, 53% on drugs). The 
observational data were mostly from registries (8/19, 42%) and electronic medical records (6/19, 32%) 
routinely collected in various countries. 
MSM-studies were published between 2001 and 2014 and RCTs between 1968 and 2017. In total, 133 
of 168 RCTs were clearly published before the date of publication of the MSM-study (79%). For 11 
(58%) of the 19 MSM-studies, all corresponding RCTs were published before the MSM-study.  
Agreement of treatment effects 
Overall 1039570 patients (median of 9939 patients per clinical question, IQR 990 to 51037) were 
evaluated from causal modelling studies and 141 corresponding RCTs were identified with overall 
120669 patients (median of 229 patients per RCT, IQR 68 to 946) for the 19 clinical questions included 
in the main analysis.  
The direction of effect estimates was in opposite directions in 8 of 19 clinical questions (42%). In 9 of 
19 (47%) clinical questions, the 95% confidence interval of the MSM-studies did not include the RCT 
treatment effect estimate (Table 2). In 9 clinical questions (47%), the two designs differed on whether 
or not they showed statistically significant differences between the compared treatments (significant 
differences found only by MSM-studies in 8 cases, and only by RCTs in 1 case), and in 4 of these 9 
clinical questions, the point estimates of the two designs were in opposite directions. The 95% 
confidence intervals for one or both designs were typically large, thus the estimates differed beyond 
chance in only 1 of the 19 clinical questions (i.e. the 95% confidence interval of the ROR excluded 1). 
The absolute deviation of effect sizes between study designs across all 19 clinical questions was 1.29-
fold (summary OR 1.29 95% confidence interval 1.12 to 1.48). When we summarized the RORs, we 
found a non-significant trend for more favorable results for the experimental treatments estimated by 
non-randomized studies with causal modelling than by RCTs (summary ROR 1.14; 95% confidence 
interval 0.93 to 1.41; Table 2; Figure 2). The non-randomized studies tended to have more favorable 
results for the experimental treatment when there was more evidence from RCTs previously available 
(meta-regression p = 0.037).  
In all sensitivity analyses (Table 2), the absolute deviations of effect sizes between study designs were 
quite similar, ranging from 1.18-fold to 1.72-fold. Causal modelling studies with a clear focus on guiding 
healthcare decisions and making clinical interpretations systematically overestimated benefits of 
experimental treatments (summary ROR 1.34; 95% confidence interval 1.03 to 1.75). Causal modelling 
studies underestimated treatment benefits when only trials that were published after the MSM-study 
were included (summary ROR 0.73; 95% confidence interval 0.48 to 1.11). 
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Discussion 
Principal findings 
This comprehensive meta-epidemiological analysis found that results of non-randomized “real world” 
studies using causal modelling with MSM frequently do not agree with RCTs evaluating the same 
clinical question. Although our results need to be interpreted with caution due to the limited sample 
size, the principal finding was that MSM-study results deviate from RCTs 1.29-fold and show greater 
benefits of experimental treatments than RCTs. The direction of treatment effects estimated with 
causal models is often opposite to that estimated in RCTs (43%), and their 95% confidence intervals 
provide little guidance to tell what RCTs on the same topic would show. When causal modeling studies 
focus on healthcare decision making, they systematically and significantly exaggerated clinical benefits. 
Comparison with other studies  
To our knowledge, this is the first systematic empirical study on how treatment effect estimates 
derived from non-randomized studies using causal modelling analyses agree with RCTs.40 Previous 
evaluations of the credibility of results from “real world” non-randomized evidence analyzed with 
causal modeling were based on comparisons with trials in very specific and selected situations.11 18 41 
This study evaluated all MSM-studies identified with a large, reproducible, highly sensitive search 
strategy. Overall, our findings are very similar to recent analyses of “real world” evidence based on 
propensity scores.35 Assumptions that reported results from observational data analyses are 
substantially influenced by knowledge of expected treatment effects from RCTs receive further 
support.35 
Limitations  
This study has some limitations that merit closer attention. First, although we found 98 MSM-studies, 
our final sample covered only 19 of them. For the other studies and their clinical questions, we did not 
find any relevant randomized trial. We sought for close agreement of the research questions in both 
study designs to minimize bias. There may have been more clinical questions that our search did not 
capture as it was widely based on published systematic reviews. However, conducting more than 300 
de-novo, high-quality systematic reviews for all clinical questions with sensitive search strategies to 
identify, assess, and extract any individual trials would not have been feasible. However, our citation-
based searches rarely detected randomized evidence and also the large number of empty reviews (i.e. 
reviews that searched for pertinent trials on a clinical question but did not find any) indicates that for 
numerous clinical questions there is indeed no trial. Overall, the clinical fields covered by our sample, 
with many questions in the field of HIV, nephrology, and on drug effects, are very similar to the overall 
use of MSM in observational research. 
Second, several MSM-study authors have known the results from pre-existing RCTs on the explored 
topic, and some explicitly used them to improve their modelling, illustrate methodological aspects or 
to compare treatment effects between the study designs. Most of the MSM-studies were published 
after the corresponding RCTs and MSM-study authors cited a corresponding RCT or systematic review 
for almost half of the clinical questions (45%). This may have created publication or reporting bias as 
it may affect the decision to report or publish results that are in strong disagreement with pre-existing 
trial evidence. A clean approach avoiding such influences and resembling the natural situation of 
decision-making in the absence of clinical trial evidence and comparison with subsequently generated 
knowledge35 was not possible. These mechanisms may have resulted in a better agreement between 
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MSM-studies with RCTs in situations with existing trial evidence. This is supported by the results from 
the meta-regression showing an association of prior RCT knowledge with observational estimates and 
also by the sensitivity analysis excluding the three MSM-studies focusing on statistical methodology. 
Third, from the trials, we preferred intention-to-treat analyses as they theoretically allow causal 
estimation of effects and are most robust against biases. This approach may lead to smaller treatment 
effect estimates in the trials especially with high rates of treatment switching and missing data and no 
active control.42 43 However, excluding clinical questions with no active controls resulted in even larger 
absolute differences between the study designs. Excluding trials with high rates of treatment switching 
or missing data and high risk of bias also showed larger absolute deviation of effects. However, the 
reporting quality was often insufficient and for many trials the switching rates, attrition and risk of bias 
were unclear. Conceptual divergences between starting and adhering to the treatment instead of the 
intention to treat43 44 were difficult to assess as the reporting was often also unclear in the MSM-
studies, which is a known problem.41 Although such theoretical issues may explain some of the 
observed differences between both designs, more and better reported information would be needed 
for further evaluation. Clinical conclusions of the MSM-studies never highlighted this issue. Any 
interpretation in this regard should be made with caution.  
Fourth, we decided not to assess the quality or risk of bias of the MSM-studies as this is not 
straightforward in observational studies, particularly in those using MSM. The recently published 
ROBINS-I tool (“Risk Of Bias In Non-randomised Studies of Interventions”) is the only suitable 
instrument we are aware of but it only asks general questions on time-varying confounding.44 The 
critical assumption for unbiased causal inference in observational research is that all relevant 
confounders are known, correctly measured, and precisely integrated in the analyses. The absence of 
unmeasured confounding has been explicitly stated by many of the study authors but typically without 
clear justifications or calls for caution. It would be entirely subjective to judge whether confounders or 
other known or unknown factors were truly irrelevant, which would be a prerequisite of a low risk of 
bias. It is generally unlikely that confounding would be completely eliminated, for example, when 
patient preferences and values determine treatment choice or adherence and outcomes. 
Overall, it is important to note that our evaluation neither intended to nor can compare the theoretical 
advantages of causal modelling versus well conducted randomized trials. Instead, we aimed to 
compare results of published evidence on treatment effects derived from studies reporting the use of 
such approaches as health care decision makers such as clinicians would use them as guidance. The 
main focus of three of the MSM-studies was not the support of healthcare decision making but 
statistical methods. They were done under more extraordinary circumstances with selected topics and 
data sources, much larger and clearer existing randomized evidence, and overall more exemplary 
characteristics than studies conducted by researchers who focus more on guiding every day healthcare 
decisions. When we only included “real world” evidence clearly focusing on guiding healthcare 
decisions, the difference between study designs was larger with a clear overestimation of clinical 
benefits beyond chance in the MSM-studies compared to RCTs. 
 
Conclusion 
The use of non-randomized “real world” evidence in the context of health care decision-making needs 
to be seen with caution. Causal modelling may have theoretical advantages and offer valuable insights 
but only when certain assumptions hold true. The critical assumptions that all factors which may bias 
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the results are known, correctly measured, and precisely included in the models may be unrealistic. 
Available randomized evidence on treatment effects may influence reported results of non-
randomized studies which adds further uncertainty to situations in which decisions must be made 
without any trial evidence. When randomized trials are unavailable and clearly unfeasible, decision 
makers may rely on such analyses, but they should be very aware that benefits may often be smaller 
and more uncertain than non-randomized “real world” evidence suggests – despite causal modelling 
with marginal structural models. To better protect patients from hazardous consequences of 
misguided decisions from non-randomized analyses, efforts should be undertaken to generate, 
whenever possible, randomized “real world evidence”, such as simple, large, pragmatic trials that 
address critically important clinical questions and guide health care more reliably.  
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Tables 
 
Table 1: Description of clinical questions evaluated in non-randomized studies using marginal structural models and corresponding randomized 
trial evidence 
MSM-study Total no. of patients 
in MSM-study / 
corresponding RCTs 
Clinical question* Country 
Data source 
Collection period  
Danaei 201336 74806 / 70902 Statins in cardiovascular disease prevention on fatal or non-fatal 
myocardial infarction 
UK 
The Health Improvement Network (THIN) 
database electronic medical records 
2000-2006 
de Beaudrap 
200839 
217 / 1067 Efavirenz vs. nevirapine in HIV-infected patients receiving 2 
nucleoside reverse transcriptase inhibitors ** 
Senegal 
“Initiative Sénégalaise d’Accès aux 
Medicaments Anti-rétroviraux” ISAARV 
prospective cohort 
1998-2002 
Delaney 200937  9939 / 21847 Beta-blocker after myocardial infarction UK 
General Practice Research Database (GPRD) 
records 
2002-2004 
Gibbons 201445  55284 / 2741 Antidepressants in children on suicide attempts and self-inflicted 
injuries 
USA 
Medical claim database: MarketScan 
2004-2009 
Hernan 200116  2168 / 823 Pneumocystis jiroveci pneumonia-prophylaxis in HIV-infected 
patients 
USA 
Multicenter AIDS Cohort Study (MACS) dataset  
1984-1991 
Hernandez 201232 990 / 51 Angiotensin-converting enzyme inhibitors and/or angiotensin II 
receptor blockers in renal transplant recipients *** 
Spain 
Regional transplant center database medical 
records 
1996-2005 
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HIV Causal 
Collaboration 
201131 
20971 / 4685 Antiretroviral therapy initiation based on CD4 cell count Multinational**** 
Cohorts 
1996-2009 
Hocqueloux 
201246  
352 / 887 Ritonavir-boosted vs. unboosted atazanavir in HIV-infected 
patients receiving 2 nucleoside reverse transcriptase inhibitors 
on virological failure 
France 
COREYA study (COhort with REYAtaz); 
retrospective cohort of electronic database 
2004-2011 
Kainz 200947 1219 / 2647 Mycophenolate mofetil vs. azathioprine in renal transplant 
patients 
Austria 
Austrian Dialysis and Transplant Registry 
OEDTR, Vienna Kidney Biopsy Registry and 
subsets of the EUROTRANSPLANT databases 
1996-2005 
Khanal 201248 146 / 561 Prolonged intermittent renal replacement therapy vs. 
continuous renal replacement therapy in acute kidney injury or 
acute-on-chronic kidney disease 
New Zealand 
Middlemore Hospital clinical records 
2002-2008 
Lukowsky 201349 23718 / 38 Peritoneal dialysis vs. hemodialysis USA 
Database records from the US Renal Data 
System (USRDS) and DaVita 
2001-2006 
Marshall 201150 26016 / 38 Peritoneal dialysis vs. conventional facility hemodialysis Australia and New Zealand 
Dialysis and Transplant Registry 
1996-2007 
Mehrotra 201151 684426 / 38 Peritoneal dialysis vs. hemodialysis USA 
National registry for all patients with ESRD 
2002-2004 
Petersen 200752 988 / 130 Boosted double vs. boosted single protease inhibitor in HIV 
infected patients 
USA 
Kaiser Permanente Medical Center patients 
1998-2005 
Sterne 200553 1276 / 8389 Triple vs. dual antiretroviral therapy in HIV-infected patients on 
AIDS or death 
Switzerland 
Swiss HIV Cohort Study records 
1996-1999 
Teng 200554 51037 / 112 Injectable vitamin D in patients on chronic hemodialysis  USA 
Medical records of dialysis facilities 
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1996-2002 
Tentori 200955 38066 / 597 Vitamin D in patients on dialysis France, Germany, Italy, Japan, Spain, UK, USA, 
Australia, Belgium, Canada, New Zealand and 
Sweden 
Dialysis Outcomes and Practice Patterns Study 
(DOPPS) medical records 
1996-2007 
Tiihonen 200956 66881 / 2356 Antipsychotics in schizophrenia Finland 
Nationwide registers 
1996-2006 
Wiesbauer 200857 2041 / 2760 Statins in renal transplant recipients Austria 
Austrian Dialysis and Transplant Registry 
1990-2005 
*) The comparator was usual care/no treatment and the outcome all-cause mortality if not specified otherwise 
**) Further outcomes evaluated were virological success (2250 patients included in corresponding RCTs), virological failure (n=1571), treatment discontinuation 
for any reason (n=1648), new CDC-C event (n=1215) 
***) Further outcome evaluated was death-censored graft failure (114 patients included in corresponding RCTs)  
****) UK CHIC (United Kingdom Collaborative HIV Cohort), ATHENA (AIDS Therapy Evaluation Netherlands), FHDH-ANRS CO4 (French Hospital Database on HIV—
Agence Nationale de Recherches sur le SIDA), SHCS (Swiss HIV Cohort Study), PISCIS (Proyecto para la Informatización del Seguimiento Clinico-epidemiológico de 
la Infección por HIV y SIDA [Spain]), CoRIS (Cohorte de la Red de Investigación en SIDA), US VACS-VC (United States Veterans Aging Cohort Study–Virtual Cohort), 
UK Register of HIV Se-roconverters, ANRS PRIMO and ANRS SEROCO (Agence Nationale de Recherches sur le SIDA, France), GEMES (Grupo Español Multicéntrico 
para el Estudio de Seroconvertores-Haemophilia) 
Abbreviations: AIDS: Acquired immune deficiency syndrome; CDC-C event: Centers for Disease Control and Prevention classification system for HIV-infection, 
category C: severely symptomatic; HIV: human immunodeficiency virus; MSM-Study: non-randomized study using marginal structural models 
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Table 2: Agreement of treatment effects from non-randomized studies using marginal structural models and randomized trial evidence 
Analysis Absolute 
deviation* 
(95% CI) 
Heterogeneity 
(95% CI) 
Summary ROR 
(95% CI) 
Heterogeneity 
(95% CI) 
No. of clinical questions n (percent) 
Total Point 
estimates of 
MSM-study 
and RCTs 
have 
opposite 
directions 
Point estimates 
of MSM-study 
and RCTs have 
same direction 
and exclude the 
null effect 
95% CI of 
MSM-study 
exclude the 
RCTs’ point 
estimate 
95% CI of ROR 
excludes the null 
effect  
Main analysis 1.29 (1.12 to 1.48) 
0% (0 to 43%) 
1.14 (0.93 to 1.41) 
30% (0 to 59%) 
19 8** (42%) 2 (11%) 9 (47%) 1 (5%) 
Sensitivity analyses        
Fixed-effect model 1.27 (1.12 to 1.44) 
0% (0 to 43%) 
1.11 (0.98 to 1.26) 
31% (0 to 59%) 
19 8** (42%) 2 (11%) 9 (47%) 2 (11%) 
MSM-studies with a clear 
focus on guiding treatment 
decisions 
1.61 (1.28 to 2.02) 
0% (0 to 45%) 
1.34 (1.03 to 1.75) 
19% (0 to 55%) 
16 7** (43%) 1 (6%) 9 (56%) 1 (6%) 
Only RCTs published before 
the MSM-study  
1.29 (1.11 to 1.49) 
0% (0 to 45%) 
1.26 (1.00 to 1.59) 
30% (0 to 60%) 
16 8** (50%) 2 (13%) 8 (50%) 1 (6%) 
Only RCTs published after 
the MSM-study 
1.39 (0.92 to 2.09) 
0% (0 to 61%) 
0.73 (0.48 to 1.11 
0% (0 to 61%) 
6 3** (50%) 0 (0%) 2 (25%) 0 (0%) 
 
 46 
Mortality outcomes only 1.26 (1.08 to 1.48) 
0% (0 to 47%) 
1.16 (0.88 to 1.54) 
36% (0 to 65%) 
14 8** (57%) 1 (7%) 9 (64%) 1 (7%) 
Non-mortality outcomes 
only 
1.42 (1.17 to 1.73) 
0% (0 to 56%) 
0.98 (0.70 to 1.37) 
58% (0 to 79%) 
8 0 (0%) 2 (25%) 2 (25%) 1 (13%) 
Active comparators only  1.72 (1.29 to 2.30) 
0% (0 to 53%) 
1.31 (0.86 to 1.99) 
44% (0 to 72%) 
10 4 (40%) 1 (10%) 4 (40%) 1 (10%) 
Non-active comparators 1.18 (1.01 to 1.38) 
0% (0 to 54%) 
1.04 (0.88 to 1.23) 
3% (0 to 56%) 
9 4** (44%) 1 (11%) 5 (56%) 0 (0%) 
Excluding RCTs with high risk 
of bias, >10% missing 
outcome data or >10% 
treatment switch 
1.43 (1.16 to 1.75) 
0% (0 to 56%) 
0.97 (0.70 to 1.34) 
50% (0 to 76%) 
8 3 (38%) 1 (13%) 4 (50%) 1 (13%) 
* Summary OR 
** Including one study where the MSM-effect estimate is below 1 and the RCT-effect estimate is exactly 1 
CI: Confidence Interval; RCT: randomized controlled trial; MSM-Study: non-randomized study using marginal structural models 
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Figures 
 
 
Figure 1: Study selection process  
MSM-Studies: non-randomized studies using marginal structural models; RCT: randomized controlled 
trial 
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Figure 2 Treatment effects estimated with non-randomized studies using marginal structural 
models and randomized trial evidence 
Left panel shows effect estimates (odds ratios) and 95% confidence intervals (CIs) of healthcare 
interventions on different outcomes reported in 19 non-randomized studies using marginal structural 
models for causal modelling (lower graphs; red diamonds indicate treatment effect estimates and lines 
indicate the 95% CIs) and in randomized controlled trials investigating the same clinical question 
(upper graphs; blue diamonds and lines). 
Right panel shows for each clinical question the ratio of outcome effects reported in non-randomized 
studies versus randomized trial evidence (as relative odds ratios, ROR, with green squares as effect 
estimate and lines as 95% CIs). The combined summary ROR (random-effects meta-analysis of RORs) 
across all 19 clinical questions is shown as diamond. Values greater than 1 indicate more favorable 
results for the experimental treatment by non-randomized studies using causal modelling. 
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Webappendix 
 
Search strategy for non-randomized studies using marginal structural models 
Search terms  Hits 
((IPTW[tiab] OR "inverse probability"[tiab]) OR (marginal[tiab] AND 
structur*[tiab] AND model*[tiab]) OR (marginal[tiab] AND "models, 
structural"[mh])) NOT (ANIMALS[mh] NOT HUMANS[mh]) 
1629 
Search date: 15 October 2014 
Database and Interface: PubMed 
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III “Treatment effects from marginal structural models in randomized 
clinical trials: meta-epidemiological analysis”  
Ewald H, Speich B, Ladanie A, Bucher HC, Ioannidis JPA, Hemkens LG 
 
Status 
The manuscript is ready for submission. Submission to Trials is planned for March 2018. 
Abstract 
Objective 
Marginal structural models (MSMs) are increasingly used to estimate causal effects of treatments, 
typically in non-randomized studies. They are one method to deal with time-dependent confounding 
arising from non-adherence. We determined how MSMs are used in randomized clinical trials (RCTs) 
and compared their results against those obtained with intention-to-treat (ITT) or other analyses. 
Study Design and Setting 
We systematically searched PubMed, Scopus, citations of key references, and Clinicaltrials.gov till May 
2017. We included RCTs reporting effects of any health care interventions based on MSMs and on at 
least one other (ITT, as treated, per protocol) analysis. 
Results  
We included 12 RCTs published between 2002 and 2016 including a median of 1972 patients 
(interquartile range (IQR) 870 to 17006) reporting 138 analyses for 24 treatment comparisons (median 
6 analyses, IQR 3 to 7 per comparison). On average, the largest reported effect estimate from any 
analysis was 1.19-fold (median on a relative risk scale; IQR 1.13 to 1.34) larger than the smallest 
reported effect estimate for the same comparison. All MSM and ITT-based results were in the same 
direction and had overlapping 95% confidence intervals, and in 71% (12 of 17 with CI) they also agreed 
on the presence or not of nominal statistical significance. For 13 of 20 comparisons (65%), MSM-based 
relative risks were more extreme (deviated more from the null) than ITT (p=0.18) (median, 1.11-fold 
(IQR 0.99 to 1.22)). The MSM- and ITT-based estimated relative risks differed on median 1.12-fold (IQR 
1.02 to 1.22).  
Conclusion 
MSMs typically provided similar results as ITT and other available analyses. Some of the differences in 
effect estimates or nominal significance may nevertheless become important in clinical decision 
making, but also require utmost attention of possible selective reporting bias. 
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Introduction 
Randomized clinical trials (RCTs) are usually the best way to measure causal effects of treatments. RCTs 
allow to measure the causal effect of being assigned to a treatment using the intention-to-treat (ITT) 
approach [1], and they may allow to estimate the effect of initiating and continuously being adherent 
to the treatment using the “per protocol” (PP) or “as treated” (AT) approach [2].  
Trials may be designed to answer clinical questions about the practical consequences of deciding to 
initiate a treatment, such as prescribing an antibiotic, beginning a life-style intervention or a treatment 
which requires good adherence. Ideally, the decision to initiate a treatment (the “intention to treat”) 
is followed by an actual start of the treatment with close adherence to the protocol. Randomization 
allows to measure effects of such decisions without confounding baseline variables. Such trials 
focusing on health care decision making are often pragmatic or practical [3]. Explanatory or 
mechanistic trials aim to better understand the underlying causal pathways of the decisions, such as 
biological mechanisms of treatment effects, or effects specifically in highly-motivated patients with 
high probability to be compliant to study protocols [3]. For such research questions, PP effects 
(evaluating only patients who adhere to the study protocol) or AT effects (evaluating patients 
according to the treatment they received, not the treatment they were assigned to) may be of specific 
interest. The conceptual difference of the ITT and PP effects (or estimands) has gained more attention 
for clinical trial design recently, for example through the ICH E9 (R1) addendum on estimands [4]. With 
perfect adherence to the treatment strategy and study protocol, ITT, PP, and AT results would be 
identical. Compared to PP and AT effects, ITT effects are theoretically unbiased estimates of the 
randomly assigned treatment regardless of the adherence [2], but they may increasingly deviate from 
PP and AT effects with increasing non-adherence. The reasons for adherence are frequently not 
random but associated with prognostic factors (e.g. sicker patients may have more difficulties to follow 
the intended treatment schedule, or they may be more motivated to adhere to the treatment). When 
there are confounding factors which are associated with both adherence and the outcome of interest, 
unadjusted PP or AT analyses would be biased. Such confounding factors may be prognostic factors 
available at baseline, such as age, disease stage, or preferences and values of patients. Standard 
statistical approaches adjusting for such variables at baseline may, at least theoretically, address some 
of this confounding. However, there are often also time-varying confounders, which also include the 
randomly assigned treatments that the study aims to explore [2]. This can, for example, be unsatisfying 
weight loss leading to non-adherence to a demanding workout intervention. In such cases, standard 
approaches for confounder control could be inappropriate [5].  
Marginal structural model (MSM) analyses are used to adjust for confounding in observational 
research [5, 6] and they can address time-varying confounding. If the relevant confounders are known, 
measured and adequately implemented in the modelling [5], MSM should theoretically allow to 
provide valid estimates of the PP and AT effect.  
Beyond conceptual considerations and frameworks, there is to our knowledge no comprehensive 
empirical evaluation of using MSM analyses in clinical trial research. We conducted a meta-
epidemiological analysis aiming to systematically identify situations where MSM analyses have been 
used in RCTs, understand why these analytical approaches were chosen, how answers to clinical 
questions agree between these different clinical trial analysis approaches and how this may impact 
health care decision making [7]. We specifically focused on the relationship of MSM-based effects and 
results from ITT analyses. 
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Methods 
Search 
We conducted four separate searches. First, we searched PubMed using textwords and the medical 
subject heading for MSM applying the Cochrane sensitivity- and precision-maximizing RCT filter [8] 
(Webappendix 1). Second, we used the citation search function in Web of Science to screen the titles 
and abstracts of all articles cited by potentially relevant studies identified through the PubMed search. 
Third, we screened all references and citations of 12 key references (selected by expert opinion of the 
authors group) in the field of MSMs [9-20]. Fourth, we also used and updated the search strategy from 
a related ongoing project in which we compared the effects from non-randomized studies using MSMs 
with those from systematically identified RCTs not using MSMs. All full-text publications were assessed 
by two independent reviewers (HE, and one of AL, BS) and disagreements were resolved by discussion 
or with a third reviewer (LGH). 
Selection of studies  
We included any RCT (including re-analyses of RCTs) that reported the effects of any health care 
intervention analyzed using MSM and at least one effect from an ITT, as treated or per protocol 
analysis. When we were unsure whether a reported effect was analysed using MSM analysis, ITT, or 
another approach, we asked authors by email for clarification. We contacted authors of 54 trials, in 
which the use of MSM analysis was not clearly stated but alluded to, to clarify whether or not MSM 
analysis was used at all and also to analyze the randomized comparison (response rate 52%). For 23 
effect estimates from 8 included RCTs [21-28] where we could not clearly determine the ITT effect, we 
contacted the trial authors for clarification (response rate 88%). We did not verify the methodology of 
these approaches but relied on the reported description of the methods in the articles or responses to 
requests, i.e. when the authors described their approach using the words “marginal structural 
models”, “intention to treat”, “as treated”, “per protocol”, or semantic variations thereof. No other 
eligibility criteria were applied.  
For each eligible RCT, we searched the first publication reporting the results of the primary endpoint 
(typically the “main” publication). We also searched trial protocols to obtain supplemental information 
on pre-specification of analyses and to clearly determine the primary outcomes (e.g. by evaluating 
details of the sample size calculation). To identify these publications, two reviewers (HE, BS) 
independently screened the reference lists of the MSM-publications, trial homepages, PubMed, and 
clinicaltrials.gov.  
Data extraction  
From each eligible RCT, we selected all clearly MSM-based effects on any outcome using any metric 
(in one case [29], both risk difference and hazard ratio were reported and we extracted only the hazard 
ratio). For each reported MSM-based effect, we identified any corresponding non-MSM-based effect 
in the same publication and the main trial publication (where applicable) that was based on the same 
comparison (i.e. population, intervention, control, outcome) and follow-up time-point (allowing for up 
to 12 month deviance). We specifically identified any effect from ITT and other analyses such as 
analyses reported as “per protocol” or “as-treated”. We extracted the MSM-based and corresponding 
non-MSM-based effect estimates (with 95% confidence intervals), and details on the analysis 
approaches. For two comparisons of one trial with continuous outcomes, there was no between-group 
difference and we calculated it using the reported changes from baseline [30, 31]. We extracted the 
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effects for the overall trial population where possible. In one case, we extracted the results for two 
mutually exclusive subpopulations (aspirin users and non-users) as no MSM-effect was reported for 
the overall population [24]. In three other cases, the MSM-based effect was only reported for a 
subpopulation of the main trial [23, 32, 33] and we only used non-MSM analyses for the same 
subpopulation.  
We extracted general trial characteristics, determined the primary endpoint and whether an MSM 
analysis was pre-specified according to the protocol or clear statements in the study publications. To 
determine why MSM analyses are used in RCTs, we extracted any statements on the authors’ 
motivations for using MSMs. 
Data analysis 
For each eligible trial and outcome, we specifically juxtaposed MSM-based with ITT-based results as 
well as MSM-based with any other results.  
Firstly, using the results from all available analyses, we assessed how frequently treatment effects 
reported from MSM and other analyses were in the same or in opposite directions, how often there 
was no overlap between the 95% CIs of the results, and how often the MSM-based effect lay within 
the 95% CI of the other effects. We also determined the overall vibration of treatment effect estimates 
per comparison, i.e. the spread between the largest and smallest effect size (on a relative risk [odds 
ratio or hazard ratio] scale) derived from different analytical methods on the same comparison [34], 
excluding two trials where we only had effects for continuous outcomes. 
Secondly, to specifically focus on MSM-based versus ITT-based results across all comparisons, we 
selected the main MSM- and main ITT-based effect for each comparison. When multiple variations of 
such effects were reported, we selected the one described as “main” or “primary” (in the MSM-
publication for the MSM-based effect and in the main publication for the ITT effect). When this was 
unclear, we selected the one first mentioned in the abstract (or in the results section, if none were 
mentioned in the abstract). 
Thirdly, to specifically compare the MSM- and ITT-based results on a trial level, we selected one main 
comparison of each trial. When there were multiple comparisons on different outcomes in the same 
trial, we selected the primary outcome or, if unclear, the one first mentioned. For two trials, we 
selected two comparisons (one trial compared two interventions with one control [35] and another 
used MSM for two mutually exclusive subpopulations [24]).  
We determined if MSM-based relative risk estimates for binary outcomes deviated more or less from 
the null, i.e. were more or less extreme than ITT-based effects. We tested if one approach more 
frequently provided more extreme effects than the other with the test for one proportion [36]. We 
then determined the ratio of these deviations from the null with MSM- versus ITT analysis (by 
calculating the difference between the deviations on the log-scale and then back transforming to a 
relative risk scale). For example, when the relative risk estimates are 0.5 and 2.0 with the two 
approaches, the difference from the null are identical and the ratio of the deviations is 1-fold. A ratio 
of > 1 indicates more extreme effects for MSM-based results.  
Finally, we determined how similar the estimates of MSM- versus ITT analyses are using the ratio of 
the estimated relative risks (by calculating the absolute difference between MSM-based and ITT-based 
effect sizes on the log-scale). E.g. if the relative risk estimates are 0.5 and 2.0 with the two approaches, 
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the ratio of the estimated relative risks is 4-fold. This ratio is >1 by definition as it reflects the absolute 
difference.  
We considered hazard ratios or risk ratios equivalent to odds ratios, when odds ratios were not 
available. The approximation is sufficiently accurate for modest event rates as those observed in the 
eligible trials. We used Stata 14.2, R 3.3.2 and Excel 14.0 for all analyses.  
 
Results 
The search yielded 4372 records (last searched 19 May 2017), 176 were assessed in full-text. We 
included 14 publications reporting results of 12 RCTs with a median of 1972 included patients; IQR 870 
to 17006) (Figure 1; Table 1). They were published between 2002 and 2016 (median 2013). Six of the 
12 RCTs stopped early, 4 for benefit [28, 35, 37, 38] and 2 for harm [27, 39]. The studies evaluated 
treatment effects of aspirin, anticoagulation, hormone therapy, anticancer drugs, timing of 
circumcision, antiretrovirals, dietary interventions, antipsychotics, or prevention of mishaps. In 6 of 12 
RCTs, the control was inactive, i.e. placebo [27, 28, 39], no intervention [30, 40], or delayed 
intervention [37]. They reported outcomes related to cardiology [27, 28, 39, 41], oncology [39, 42, 43], 
infectious diseases [25, 37, 38], diabetes [23], psychiatry [44], gerontology [30], and physical education 
[40] (Table 1). Double blinding was reported in 6 of 11 RCTs [27, 28, 37-39, 41]. 
For 7 RCTs [27, 28, 30, 35, 39, 41, 43], we identified a protocol or design paper. The application of MSM 
was pre-specified only in 1 of the 12 trials [30]. The first or last author of the publication presenting 
MSM-based results also co-authored the main and, where available, the protocol publication for 9 of 
12 trials [38, 39, 43]. The MSM-publication was published a median of 3 years after the main trial 
publication. The stated motivations for applying MSM were diverse: MSM was used to adjust for “time-
dependent” or “time-varying” confounding [22, 24-26, 29, 31-33, 45-47], “non-compliance” or “non-
adherence” [24, 25, 29, 31, 40, 45, 47], “loss to follow-up” [22], treatment switching [33], second-line 
treatment [32], and “to analyze the data as if it were from an observational study rather than a 
randomized, controlled trial” [23]; Webappendix 2).  
Across the 12 RCTs, we identified 24 clinical questions, i.e. comparisons (median 6, IQR 3 to 7 per 
comparison). Overall, 138 analyses were reported for these 24 comparisons of which 38 were MSM-
based (including sensitivity analyses, “crude” and adjusted analyses, different censoring, and different 
forms of MSM). For 20 of the 24 clinical questions there were ITT analyses reported (in 11 RCTs), AT 
analyses for 9 (4 RCTs), PP analyses for 3 (1 RCT), and other analyses for 5 (2 RCTs) (Figure 2). Twenty-
one comparisons had binary outcomes and 3 comparisons (2 RCTs) had continuous outcomes. 
Two analyses using MSM were clearly pre-specified (1 trial), and 4 analyses using MSM were described 
as “sensitivity analysis” (2 trials). MSM was used to evaluate the primary endpoint in 11 of the 12 RCTs. 
Overall relationship of treatment effects 
Across all 24 comparisons, the MSM-based results and those from any other reported analyses were 
all in the same direction in 19 cases (79%), overlapped with all of the 95% CIs (100%), and the MSM-
effect lay within all 95% CIs of all other effects in 19 of 22 cases (86%).  
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Among the 123 analyses reported for 21 comparisons with binary outcomes, the median spread 
between the largest and smallest effect estimate was 1.19 on a relative risk scale, i.e. the largest effect 
estimate was 1.19-fold (median; IQR 1.13 to 1.34; Table 2) larger than the smallest.  
Relationship of MSM- and ITT-based results 
MSM-based and ITT-based results were all in the same direction across all 20 available comparisons 
(100%; Table 2). Their CIs overlapped in all 18 cases with available CI information (100%), and the MSM-
effect lay within the 95% CI of ITT effects in 16 cases (89%). Twelve of 17 (71%, 3 cases with at least 1 
CI missing) had both the same direction of effect and were both nominally significant or both nominally 
non-significant (i.e. both 95% CIs included the null or not; Table 2).  
MSM-based effects were more extreme in 13 of 20 comparisons (65%); and in 7 of 20 (35%), ITT-based 
effects were more extreme (p=0.18). The median deviation from the null of the MSM-based effects 
was 1.35 (IQR 1.19 to 1.59) and of ITT effects 1.24 (IQR 1.10 to 1.29) on a relative risk scale. On average 
(median), the ratio of these deviations indicated 1.12-fold more extreme MSM-based effects than the 
corresponding ITT effects (IQR 0.99 to 1.22; Table 2).  
When analyzing only the 13 main comparisons (1 trial had no ITT-based result at all), MSM-based 
effects were more extreme than ITT-based effects in 7 comparisons (54%). In 46%, ITT-based effects 
were more extreme (p=0.78). The median deviation from the null of the MSM-based effects was 1.39 
(IQR 1.19 to 1.69) and of ITT effects 1.24 (IQR 1.15 to 1.34). Here, MSM-based effects were 1.11-fold 
more extreme (IQR 0.98 to 1.20; Table 2).  
The ratio of the estimated relative risks from MSM and ITT was 1.12-fold (IQR 1.02 to 1.22; Table 2), 
i.e. half of the MSM-based effects deviated at least 1.12-fold from ITT effects. Among the 11 main 
comparisons, this was 1.11-fold (IQR 1.02 to 1.20; Table 2). 
 
Discussion 
Principal findings 
In this empirical analysis, we found 12 trials with 138 effect estimates for 24 clinical questions 
(comparisons) which reported results from MSM-based and conventional analyses (Figure 2). The main 
motivations for using MSM were related to missing data and other protocol deviations. The differences 
between MSM-based and other effects, including ITT effects, were typically within chance and the 
effects were in the same direction. However, the quantitative differences across reported effects even 
within the same trial for the same outcome and the same author groups using different methods can 
be substantial. MSM does not consistently yield more extreme effects than ITT. Overall, MSM and ITT 
effects were similar, the absolute difference was less than 1.12-fold in half of the comparisons. 
However, while a difference of 1.12-fold may be modest for some outcomes, it may be clinically very 
meaningful for others (e.g. death).  
The substantial vibration between effect sizes from different analytic methods may be of less relevance 
for clinical decision-making as all effect estimates had the same direction. However, when quantifying 
effect estimates and their CIs across several studies (e.g. in meta-analyses, health technology 
assessments, or indirect comparisons of treatment effects), it may make a substantial difference which 
analysis method is chosen. When it comes to weighing benefits and harms of treatments or informing 
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shared decisions, for example when relative risks are translated to numbers needed to treat or harm, 
variations of effect sizes could matter.  
There were on average 6 estimates of the very same outcome (we explicitly searched for trials with at 
least 2 analyses of the same outcome and many analyses were explorative to demonstrate the analytic 
approaches). However, when publications offer several effect estimates for one and the same 
outcome, it may be difficult for healthcare decision makers to know which to base their decisions on. 
In one study, for example, there were 11 ITT effects, and many studies had two or more ITT effects. 
The analyses for these estimates followed different approaches and had different degrees of statistical 
adjustments (e.g. crude and adjusted for various covariates) [48]. Essentially, almost all of the analyses 
were not clearly pre-specified and this could add uncertainty in the results [48, 49]. In such a setting, 
the substantial vibration of effects magnifies the impact of selective reporting biases. Post hoc 
calculations of effect estimates may impact the overall assessment of treatments substantially and 
further increases the risk for misguided care or policy making. It is also unknown how many additional 
analyses, with different models and adjustments might also have been performed, yet were not 
reported at all. Our findings highlight that mere pre-specification of the outcomes (and not specifically 
the analyses thereof) in clinical trials may not be sufficient to prevent selective reporting bias. Even 
when the results for an outcome are reported for the same time-point as pre-specified in protocols 
and trial registries, the results from various statistical approaches may provide different effect sizes 
and can be selectively reported. 
Overall, the spread between the effect estimates from the statistical analyses on the very same 
outcome was substantial (1.19-fold). In the present sample of trials, the use of MSM was often an 
explorative approach. However, conducting several analytical methods in addition to the pre-specified 
analyses, especially methods as complex as MSM that give plenty of options for specification, could 
increase the risk for selective reporting of only some of the statistical analyses. Even when the 
approach itself would be pre-specified, statistical details of applying such a complex approach may still 
have great impact on the results. This complexity requires highly detailed pre-specification because of 
the possible impact of selective reporting bias, which could possibly be larger than the impact of 
selecting conceptually different analytical approaches (or estimands [4]).  
Comparison with other studies 
This is, as far as we know, the first meta-epidemiological analysis comparing the results from causal 
modelling analyses with conventional analyses within trials across all medical fields. Several empirical 
studies compared ITT and PP analyses within one medical field or a specific time range [50-52]. A re-
analysis of an RCT evaluating interventions for symptom management compared the conclusions from 
ITT (without imputing missing data) with those from PP analysis [50]. While the conclusions did not 
differ, the PP analysis also indicated which intervention and dose strategies affected symptoms [50]. 
A systematic review of RCTs reporting both ITT and PP analyses on a primary binary endpoint found 
effects from PP analyses more extreme and the ratio to ITT analyses varied greatly (0.39 to 2.53)[51]. 
In line with our findings, they concluded that protocol deviations can lead to systematic and 
unpredictable bias and that a trial’s conclusion should not be based on the effect of either ITT or PP 
alone [51]. A meta-epidemiological study compared the results from conventional ITT analyses with 
those from modified ITT analyses or non-ITT analyses. Similar to our results, they found that the ITT 
results had less extreme effects [53].  
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Limitations 
Our study has several limitations. First, we only identified 12 trials for which we had MSM- and non-
MSM-based effects and that focused on clinical decision making. Many of the excluded RCTs did not 
use MSM to analyze the randomized comparison but merely used the trial database to evaluate 
associations of non-randomized exposures or patient characteristics with outcomes.  
Second, we encountered various different forms and descriptions of MSM, e.g. standard MSM [16], 
augmented MSM, adaptively truncated MSM [46], MSM for binary and continuous outcomes [33], 
using IPTW, IPCW, IPW, G-estimation, adjusted or “unadjusted“ [40], censored at different timepoints 
[25] and adjusted for different covariates with or without two-way interactions between 
randomization status and each covariate [25]. Some of our included studies even reported the results 
of multiple different forms of MSM within their study [25, 26, 40, 46].  
Third, we did not verify the analytic approaches and relied on the authors’ descriptions of them. 
Although we believe that the authors are probably the best experts for their data and analyses and 
have correctly classified and described them, details of the definitions may still be inconsistent [54]. 
Fourth, the trials that applied MSM to analyze the randomized comparison were mainly very large and 
highly cited (median citation count of main publications 1388 (IQR 142 to 2121; SCOPUS 7 January 
2018). All but 3 studies [30, 40, 42] were among the top 1% of the related medical trial literature 
(“SCOPUS Citation Benchmarking Compared to Medicine articles of same age and document type”; 1 
study not found on SCOPUS and not counted [44]). Many (5/12) trials were also discontinued early, 
more frequently than in the typical clinical trial literature [55]. Hence our sample appears not to be 
representative of all RCTs. 
Fifth, we encountered problems with vague reporting of the analysis methods used. E.g. an analysis 
was merely described as “conventional Cox model” and it was unclear who was analyzed or how 
missing patient data were imputed. Several terms are not globally defined, e.g. “patients evaluable for 
efficacy”, “intent-to-treat subset”, or “population with observed cases”. This may confuse readers as 
they have different meanings to different people [54]. 
Sixth, the reporting of adherence, protocol violations, treatment switches, and missing data was 
typically not sufficiently clear to allow us to consider this in further analyses. We were not able to 
explore the agreement between effects sizes in relation to these factors.  
Seventh, the application of MSM in many studies was for very different reasons. MSM was sometimes 
applied by highly experienced teams of biostatisticians who developed the approach and who 
conducted the analyses post-hoc for methodological demonstration purposes and not with the direct 
intention to inform healthcare decision making. This further adds to the very limited generalizability 
of this small but nevertheless systematically derived sample of trials. 
Finally, for each outcome, we intended to extract information indicating potential problems that may 
motivate authors to use MSM or other specific models. While we found statements that clearly 
indicated such issues, the reporting quality was very heterogeneous.  
Overall, MSM analyses require more sophisticated modelling than ITT analyses. It is difficult to pre-
specify and collect the detailed high-quality data that are required for analyzing all possible post-
randomization confounders, such as non-adherence [56]. Since patients’ preferences and values 
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leading to non-adherence are almost never included in data collection, important confounders very 
likely remain unmeasured and hence cannot be included in the modelling. Therefore, probably there 
is always some residual confounding bias even in MSM-adjusted effects. Furthermore, caution is 
required to pre-specify analyses where possible and apply strict safeguards to avoid selective reporting 
or biases introduced by unblinded analyses. These limitations are less relevant in ITT analyses which 
don’t require such adjustments and are more straightforward to pre-specify. Selective reporting bias 
may have more impact on results used for decision-making than using conceptually different statistical 
approaches per se. Without very detailed and strict measures as safeguards to avoid research-
associated biases such as selective reporting, the theoretical value of this promising approach may be 
entirely neutralized under “real world” research conditions. 
 
Conclusion 
Overall, we conclude that MSM-based results in randomized trials typically agreed with ITT and other 
conventional analyses of RCTs. They may theoretically provide very helpful insights and different 
perspectives in treatment effects, especially when there are high rates of attrition and non-adherence. 
However, there is a wide spread across all reported effects for the same outcome that requires utmost 
attention and complex safeguards to prevent selective reporting bias and related problems.  
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Tables 
 
Table 1: Characteristics of included studies 
RCT No. 
Randomized 
Patients’ Condition Intervention and control Total number 
of pertinent 
comparisons 
Outcomes with MSM-based results  
Analytic approach (n) 
ACTG 320* [25, 
38] 
1156 HIV positive, 
immunosuppressed
, ART-experienced 
patients 
HAART (Zidovudine and 
Lamivudine plus Indinavir) vs 
CART (Zidovudine and 
Lamivudine) 
11 AIDS or death (primary) 
MSM (8) 
ITT (3) 
ARISTOTLE [24, 
41, 57]  
18201 
(using 
aspirin at BL: 
5632) 
Atrial fibrillation (in 
aspirin users and 
non-users) 
Apixaban vs Warfarin 6 Stroke or systemic embolism (primary, subgroups 
only) 
MSM (1) 
ITT (2) 
Major bleeding  
MSM (1) 
As treated (2) 
 18201 
(Not using 
aspirin at BL: 
12569 
  6 Stroke or systemic embolism (primary, subgroups 
only) 
MSM (1) 
ITT (2) 
Major bleeding  
MSM (1) 
As treated (2) 
CALERIE [30, 31] 220 Healthy, young- 
and middle-aged 
nonobese men and 
women 
Calorie restriction (behavioral 
approach with dietary 
modiﬁcations) vs no calorie goal 
(no dietary or behavioral 
counseling) 
6 RMR (primary) 
MSM (1) 
ITT (2) 
Core temperature (primary) 
MSM (1) 
ITT (2) 
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Kisumu * [21, 22, 
37] 
2784 Uncircumcised, 
HIV-negative young 
men 
Immediate vs delayed 
circumcision 
6 HIV incidence (primary) 
MSM (1) 
As treated (2) 
Herpes simplex virus 2 incidence 
MSM (1) 
As treated (2) 
Negoro / 
Yamaguchi [32, 
42] *** 
398 (MSM 
analysis only 
for 2 of 3 
groups with 
266 
patients) 
Stage IIIB lung 
cancer (NSCLC) 
Irinotecan hydrochloride vs 
cisplatin 
4 Overall survival (primary)  
MSM (1) 
ITT (3) 
PHS * [26, 28, 58] 22071 Male physicians Aspirin vs placebo 10 Cardiovascular mortality (primary) 
MSM (3) 
ITT (4) 
As treated (3) 
PointBreak [43, 
46, 59] 
939 Stage  
IIIB or IV lung 
cancer (NSCLC) 
"Pemetrexed/Carboplatin/Beva
cizumab followed by 
maintenance Pemetrexed/ 
Bevacizumab" vs 
"Paclitaxel/Carboplatin/Bevaciz
umab Followed by Maintenance 
Bevacizumab" 
6 Overall survival (primary) 
MSM (3) 
ITT (3) 
PREDIMED * [23, 
35] 
7447 
(Non-
diabetic 
subgroup: 
3833) 
Risk factors for CVD Mediterranean diet 
supplemented with extra-virgin 
olive oil vs advice on a low-fat 
diet 
12 Type 2 diabetes mellitus incidence  
MSM (1) 
ITT (11) 
   Mediterranean diet 
supplemented with nuts vs 
advice on a low-fat diet 
12 Type 2 diabetes mellitus incidence  
MSM (1) 
ITT (11) 
Ranapurwala [40] 1660 Recreational scuba 
divers 
Checklist vs no checklist 18 Any diving mishap (primary) 
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(70 
randomized 
units) 
MSM (2) 
ITT (2) 
Per protocol (2) 
Major diving mishaps 
MSM (2) 
ITT (2) 
Per protocol (2) 
Minor diving mishaps 
MSM (2) 
ITT (2) 
Per protocol (2) 
Tunis / Faries [33, 
44] 
664 (MSM 
analysis only 
for 2 of 3 
groups with 
443 
patients) 
Patients with 
schizophrenia or 
schizoaffective 
disorder 
Olanzapine vs “fail-ﬁrst” 
algorithm on conventional 
9 Change in brief psychiatric rating scale (primary)  
MSM (1) 
ITT (2) 
On drug (4) 
Epoch (2) 
WHI * [29, 39, 60] 16608 Postmenopausal 
women with intact 
uterus 
Estrogen-plus-progestin vs 
placebo  
7 Coronary Heart Disease (primary) 
MSM (1) 
ITT (2) 
Invasive breast cancer incidence 
MSM (1) 
ITT (3) 
WHS * [27, 45, 61] 39876 Female health 
professionals 
Aspirin vs placebo 25 Major cardiovascular events (including myocardial 
infarction, stroke, cardiovascular disease 
mortality) (primary) 
MSM (1) 
ITT (4) 
As treated (2) 
On drug (1) 
Myocardial infarction 
MSM (1) 
ITT (3) 
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As treated (1) 
On drug (1) 
Stroke 
MSM (1) 
ITT (3) 
As treated (1) 
On drug (1) 
Cardiovascular disease mortality  
MSM (1) 
ITT (3) 
As treated (1) 
* Trial stopped early 
** The main publication is based on 2 year follow up (effects not considered) 
*** The original study population were patients with untreated NSCLC stage IIIB and IV, however, MSM-based results are only available for stage III patients. 
Also, the original comparison of the study consisted of 3 treatment arms of which 2 were different doses of Irinotecan. As MSM-based results were only available 
for the comparison with the lower dose Irinotecan (60 mg m-2), we do not present the third arm (100 mg m-2). 
ACTG 320: AIDS Clinical Trial Group; AIDS: Acquired Immune Deficiency Syndrome; ARISTOTLE: Apixaban for Reduction in Stroke and Other Thromboembolic 
Events in Atrial Fibrillation trial; CALERIE: Comprehensive Assessment of the Long-term Effects of Reducing Intake of Energy; HIV: human immunodeficiency virus; 
MSM: Marginal structural models; PHS: Physicians’ Health Study; PREDIMED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet; WHI: 
Women’s Health Initiative; WHS: Women’s Health Study  
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Table 2 Relationship of effect estimates per outcome 
Comparison Vibration of treatment effect 
estimates: Spread of lowest vs. 
highest relative risk estimate 
across all reported analyses* 
Ratio of 
deviations from 
the null with 
MSM and ITT 
(x-fold more 
extreme effects 
with MSM)*# 
Ratio of the relative 
risks with MSM and 
ITT* 
(x-fold difference 
between effects) 
MSM and ITT 
effects in same 
direction 
MSM and ITT 
effects with same 
stat. significance 
MSM and ITT 
effect CI 
overlapping 
MSM effect 
within CI of ITT 
effect 
ACTG 320: AIDS or death 1,13 1,11 1,11 yes yes yes yes 
ARISTOTLE (Aspirin non-users): 
Major Bleeding  
1,05 NA NA NA 
(no ITT effect) 
NA 
(no ITT effect) 
NA 
(no ITT effect) 
NA 
(no ITT effect) 
ARISTOTLE (Aspirin users): 
Major Bleeding  
1,04 NA NA NA 
(no ITT effect) 
NA 
(no ITT effect) 
NA 
(no ITT effect) 
NA 
(no ITT effect) 
ARISTOTLE (Aspirin non-users): 
Stroke or systemic embolism  
1,02 0,98 1,02 yes yes yes yes 
ARISTOTLE (Aspirin users): 
Stroke or systemic embolism  
1,24 1,22 1,22 yes yes yes yes 
Kisumu: HIV incidence 1,18 NA NA NA 
(no ITT effect) 
NA 
(no ITT effect) 
NA 
(no ITT effect) 
NA 
(no ITT effect) 
Kisumu: HSV-2 incidence 1,14 NA NA NA 
(no ITT effect) 
NA 
(no ITT effect) 
NA 
(no ITT effect) 
NA 
(no ITT effect) 
Negoro/Yamaguchi: Survival 1,03 0,97 1,03 yes yes yes yes 
PREDIMED (EVOO): Incidence 
type 2 diabetes mellitus  
2,09 0,99 1,01 yes yes yes yes 
PREDIMED (Nuts): Incidence 
type 2 diabetes mellitus  
1,86 0,99 1,01 yes yes yes yes 
PHS: CVD mortality 1,42 1,3 1,3 yes yes yes yes 
PointBreak: Overall survival 2,06 1,12 1,12 yes NA** NA** yes 
Ranapurwala: All mishaps 1,18 1,18 1,18 yes no yes yes 
Ranapurwala: Major mishaps 1,19 1,16 1,16 yes no yes yes 
Ranapurwala: Minor mishaps 1,19 1,19 1,19 yes yes yes yes 
WHI: Coronary Heart Disease 1,37 1,31 1,31 yes no yes no 
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WHI: Invasive breast cancer 1,34 1,33 1,33 yes yes yes no 
WHS: CVD Mortality 1,24 1,24 1,24 yes yes yes yes 
WHS: Major CVD events 1,15 0,98 1,02 yes yes yes yes 
WHS: Myocardial infarction 1,09 1,09 1,09 yes yes yes yes 
WHS: Stroke 1,19 0,98 1,02 yes no yes yes 
Tunis/Faries: change in BPRS NA NA NA yes no yes yes 
CALERIE: resting metabolic rate  NA NA NA yes NA*** NA*** NA*** 
CALERIE: Core Temperature NA NA NA yes NA*** NA*** NA*** 
Median (IQR) or Total (%)  1.19 (1.13 to 1.34) **** 1.12 (0.99 to 1.22) 1.12 (1.02 to 1.22) Yes: 20/20 (100 %) 
No:     0/24 (0 %) 
Yes: 12/17 (71 %) 
No:     5/17 (29 %) 
Yes: 17/17 (100%) 
No:     0/17 (0%) 
Yes: 16/18 (89%) 
No:    2/18 (11%) 
Median (IQR) or Total (%) (main 
outcomes only) 
1.21 (1.15 to 1.53)  1.11 (0.98 to 1.20) 1.11 (1.02 to 1.20) Yes: 13/13 (100 %) 
No:     0/13 (0 %) 
Yes:   8/11 (73 %) 
No:     3/11 (27 %) 
Yes: 11/11 (100%) 
No:     0/11 (0%) 
Yes: 11/12 (92%) 
No:    1/12 (8%) 
*) dichotomous outcomes only 
**) No 95% confidence interval for the MSM-based result reported 
***) No 95% confidence interval for the MSM-based nor the ITT-based result reported 
****) The median (IQR) excluding sensitivity analyses is 1.17 (1.08 to 1.24) 
#) > 1 indicates more extreme effects for MSM-based results 
 
ACTG 320: AIDS Clinical Trial Group; AIDS: Acquired Immune Deficiency Syndrome; ARISTOTLE: Apixaban for Reduction in Stroke and Other Thromboembolic 
Events in Atrial Fibrillation trial; CALERIE: Comprehensive Assessment of the Long-term Effects of Reducing Intake of Energy; CI: confidence interval; HIV: human 
immunodeficiency virus; CVD: cardiovascular disease; EVOO: extra virgin olive oil; IQR: interquartile range; ITT: intention-to-treat; MSM: marginal structural 
models; NA: not applicable; PHS: Physicians’ Health Study; PREDIMED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet; WHI: Women’s 
Health Initiative; WHS: Women’s Health Study   
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Figures 
 
 
Figure 1: Study flow  
MSM: marginal structural models; RCT: randomized controlled trial 
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ACTG 320: AIDS or death
MSM 1
MSM 2
MSM 3
MSM 4
MSM 5
MSM 6
MSM 7
MSM 8
ITT 1
ITT 2
ITT 3
ARISTOTLE: Stroke/systemic embolism (Aspirin users)
MSM
ITT 1
ITT 2
ARISTOTLE: Stroke/systemic embolism (Aspirin non-users)
MSM
ITT 1
ITT 2
ARISTOTLE: Major Bleeding (Aspirin users)
MSM
AT 1
AT 2
ARISTOTLE: Major Bleeding (Aspirin non-users)
MSM
AT 1
AT 2
Kisumu: HIV incidence
MSM
AT 1
AT 2*
Kisumu: HSV-2 incidence
MSM
AT 1
AT 2*
Negoro/Yamaguchi: Survival
MSM
ITT
ITT
ITT**
PHS: Cardiovascular mortality
MSM 1
MSM 2 (sens.)
MSM 3 (sens.)
ITT 1*
ITT 2
ITT 3
ITT 4
AT 1*
AT 2
AT 3
PointBreak: Overall survival
MSM 1
MSM 2
MSM 3
ITT 1
ITT 2
ITT 3
PREDIMED: Diabetes (EVOO)
MSM
ITT 1*
ITT 2
ITT 3
ITT 4
ITT 5 (sens.)
ITT 6 (sens.)
ITT 7 (sens.)
ITT 8 (sens.)
ITT 9 (sens.)
ITT 10 (sens.)
ITT 11 (sens.)
PREDIMED: Diabetes (Nuts)
MSM
ITT 1*
ITT 2
ITT 3
ITT 4
ITT 5 (sens.)
ITT 6 (sens.)
ITT 7 (sens.)
ITT 8 (sens.)
ITT 9 (sens.)
ITT 10 (sens.)
ITT 11 (sens.)
Ranapurwala: All mishaps
MSM 1
MSM 2*
'ITT' 1
'ITT' 2*
PP 1
PP 2*
Ranapurwala: Major mishaps
MSM 1
MSM 2*
ITT 1
ITT 2*
PP 1
PP 2*
Ranapurwala: Minor mishaps
MSM 1
MSM 2*
ITT 1
ITT 2*
PP 1
PP 2*
WHI: Invasive breast cancer
MSM
ITT 1
ITT 2
ITT 3
WHI: Coronary Heart Disease
MSM
ITT
ITT
WHS: Major cardiovascular events
MSM
ITT 1
ITT 2
ITT 3
ITT 4
AT 1*
AT 2
Other (sens.)
WHS: Myocardial infarction
MSM
ITT 1
ITT 2
ITT 3
AT
Other (sens.)
WHS: Stroke
MSM
ITT 1
ITT 2
ITT 3
AT
Other (sens.)
WHS: CVD Mortality
MSM
ITT 1
ITT 2
ITT 3
AT
ID
Study
  
1.2 .5 1.5 2
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Figure 2: Effect estimates and 95% confidence intervals on a relative risk scale reported in 
the main publication and the publication with MSM-results on the same clinical question 
(population, intervention, control, outcome, timepoint) 
* unadjusted analyses  
ACTG 320: AIDS Clinical Trial Group; AIDS: Acquired Immune Deficiency Syndrome; ARISTOTLE: 
Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial; AS: as 
treated; CALERIE: Comprehensive Assessment of the Long-term Effects of Reducing Intake of Energy; 
CVD: cardiovascular disease; HIV: human immunodeficiency virus; EVOO: extra virgin olive oil; ITT: 
intention-to-treat; MSM: Marginal structural models; PHS: Physicians’ Health Study; PP: per protocol; 
PREDIMED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet; Sens.: Sensitivity 
analysis; WHI: Women’s Health Initiative; WHS: Women’s Health Study  
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Webappendix 1  
Search details 
Key Articles on marginal structural models 
1. Cole, Stephen R.; Hernan, Miguel A. Constructing inverse probability weights for marginal 
structural models. AMERICAN JOURNAL OF EPIDEMIOLOGY  Volume: 168   Issue: 6   Pages: 
656-664   Published: SEP 15 2008  
2. Hernan, MA; Brumback, B; Robins, JM. Marginal structural models to estimate the causal 
effect of zidovudine on the survival of HIV-positive men. EPIDEMIOLOGY  Volume: 11  Issue: 
5  Pages: 561-570  DOI: 10.1097/00001648-200009000-00012  Published: SEP 2000 
3. Hernan, MA; Brumback, B; Robins, JM. Marginal structural models to estimate the joint 
causal effect of nonrandomized treatments. JOURNAL OF THE AMERICAN STATISTICAL 
ASSOCIATION Volume: 96 Issue: 454 Pages: 440-448 DOI: 10.1198/016214501753168154 
Published: JUN 2001  
4. Hernan, MA; Robins, JM Estimating causal effects from epidemiological data. JOURNAL OF 
EPIDEMIOLOGY AND COMMUNITY HEALTH Volume: 60 Issue: 7 Pages: 578-586 DOI: 
10.1136/jech.2004.029496 Published: JUL 2006  
5. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in 
epidemiology. Epidemiology. 2000 Sep;11(5):550-60. PubMed PMID:10955408. 
6. Robins JM. Correction for non-compliance in equivalence trials. Stat Med 1998;17:269–302. 
7. Robins JM. Marginal structural models versus structural nested models as tools for causal 
inference. In: Halloran E, Berry D, eds. Statistical Models in Epidemiology: The Environment 
and Clinical Trials. New York: Springer-Verlag, 1999;95–134. 
8. Robins JM. Marginal structural models. In: 1997 Proceedings of the Section on Bayesian 
Statistical Science, Alexandria, VA: American Statistical Association, 1998;1–10. 
9. Robins, JM Association, causation, and marginal structural models. SYNTHESE Volume: 121 
Issue: 1-2 Pages: 151-179 DOI: 10.1023/A:1005285815569 Published: NOV 1999  
10. Robins, JM; Greenland, S; Hu, FC. Estimation of the causal effect of a time-varying exposure 
on the marginal mean of a repeated binary outcome. JOURNAL OF THE AMERICAN 
STATISTICAL ASSOCIATION  Volume: 94  Issue: 447  Pages: 687-700  DOI: 
10.2307/2669978  Published: SEP 1999 
11. VanderWeele, Tyler J. Marginal Structural Models for the Estimation of Direct and Indirect 
Effects. EPIDEMIOLOGY  Volume: 20   Issue: 1   Pages: 18-26   Published: JAN 2009  
12. Suarez D, Borras R, Basagana X. Differences between marginal structural models and 
conventional models in their exposure effect estimates: a systematic review. Epidemiology 
(Cambridge, Mass.). 2011;22(4):586-588. 
Search on Pubmed, 2 June 2016 
(IPTW[tiab] OR "inverse probability"[tiab] OR (marginal[tiab] AND structur*[tiab] AND model*[tiab]) 
OR (marginal[tiab] AND "models, structural"[MeSH Terms])) NOT (ANIMALS[MH] NOT 
HUMANS[MH]) AND (randomized controlled trial[pt] OR controlled clinical trial[pt] OR 
randomized[tiab] OR placebo[tiab] OR "clinical trials as topic"[MeSH Terms:noexp] OR 
randomly[tiab] OR trial[ti] NOT ("animals"[MeSH Terms] NOT "humans"[MeSH Terms])) 
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Webappendix 2 
 
Included RCT MSM used for Statements  
ACTG 320 [25] Time-dependent 
confounding 
Non-compliance 
“Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of 
randomized highly active antiretroviral therapy on incident AIDS or death” 
ARISTOTLE [24] Time-dependent 
confounding 
Non-compliance 
"In addition to adjusting for baseline variables associated with either the propensity to use aspirin or the outcomes 
of interest, we used marginal structural models to further adjust for potential time-dependent confounders to 
estimate a HR for the effect of aspirin on outcome, and to test for interaction between aspirin use and the 
randomized treatment (apixaban vs. warfarin)."  
“Results from marginal structural model analyses that accounted for whether a patient was actually taking aspirin 
at the time of their bleeding event resulted in similar ﬁndings”  
CALERIE [31] Time-dependent 
confounding  
Non-adherence 
“Application of the marginal structural model to account for suboptimal adherence in a randomized controlled trial” 
- “First, stepwise linear regression was used to model the observed percent weight loss, while stepwise logistic 
regression model was applied to model early discontinuation from the intervention.” 
- “This model is complicated and requires careful attention to detail. Which variables to force into the ancillary 
models, how to construct interaction terms, and how to address time-dependent covariates must be 
considered.” 
- “However, adherence is an endogenous variable and satisﬁes the deﬁnition of a time-dependent confounder.” 
“The dataset is then analyzed using a logistic regression model including a term for the time interval as well as the 
ﬁxed and time-dependent covariates of interest.” 
Kisumu [21, 22] Time-dependent 
confounding and 
loss to follow-up 
"Marginal structural models reduce the bias introduced by self-selection to become circumcised through 
application of stabilized weighting at each time point for the time-dependent confounders." 
"For our marginal structural approach, we generated the above described stabilized IPTW and stabilized inverse-
probability-of-censoring-weights (IPCWs) to account for time-dependent confounding and loss to follow-up." 
Negoro/Yamaguchi 
[32] 
Time-dependent 
confounding 
Secondline 
treatment 
“In our companion paper [8], we propose to use structural nested models (SNMs) [9, 10] and marginal structural 
models (MSMs) [10–12] to adjust for differential proportions of second-line treatment. In this paper, we deal with 
clinical application of the two models in detail.” 
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“Unlike the usual time-dependent Cox model, the marginal structural Cox model can be used to obtain valid causal 
inference for the effect of time-varying treatment in the presence of time-dependent confounders which satisfy 
the condition (i) and (ii) introduced in Section 3.1.” 
PHS  [26] Time-dependent 
confounding 
"The authors used a marginal structural model with time-dependent inverse probability weights to estimate the 
underlying causal effect of aspirin on cardiovascular mortality."  
"For comparison to the estimates derived from the marginal structural models, we also estimated the effects of 
aspirin from standard intention-to-treat and as-treated analyses. For comparability, we used pooled logistic 
regression in these analyses, both with and without the usual adjustment for time-varying covariates in time-
dependent models."  
PointBreak [46] Time-dependent 
confounding 
“Marginal structural models (MSMs) have been applied to estimate causal treatment effects even in the presence 
of time-dependent confounders.” 
PREDIMED [23] To analyze the data 
As if it were from an 
observational study 
rather than a 
randomized, 
controlled trial 
"We used the marginal structural model to provide the results of an alternative technique to analyze the data as if 
it were from an observational study rather than a randomized, controlled trial." 
Ranapurwala [40] Non-adherence "Marginal structural models were used to account for non-adherence." 
Tunis/Faries [33] Treatment 
switching  
Time-dependent 
confounding 
“Various methods of eliminating the switching, such as epoch analyses and on-drug subset analyses, along with 
use of marginal structural models generated reasonably consistent non-zero treatment effect estimates.” 
“The MSM retains the repeated measures structure of the data and directly addresses time-varying covariates 
while the epoch approaches handles such variables as baseline confounders for the next episode and assesses a 
different parameter (change from baseline to endpoint of a naturalistic episode of treatment)." 
“We were particularly interested in the performance of marginal structural modeling (MSM)—as this approach 
utilizes all of the study data and produces consistent estimates of the causal effect of treatments, even when there 
are treatment switching and time-varying confounders.” 
WHI [29, 47] Time-dependent 
confounding  
Non-adherence 
"Inverse probability weighting of marginal structural models has been used to adjust for nonadherence, but most 
studies have provided only relative measures of risk."[47] 
“Therefore there is no need to estimate separate inverse probability weights to adjust for selection bias due to 
artificial censoring because the treatment weights estimated in the primary analysis already adjust for the potential 
time-varying selection bias due to artificial censoring.”[47] 
“Adherence-adjusted hazard ratios and CHD-free survival curves estimated through inverse probability 
weighting.”[29] 
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WHS  [45] Time-dependent 
confounding  
Non-compliance 
"We used marginal structural models (MSMs) to estimate the etiologic effect of continuous aspirin use on CVD 
events among 39,876 apparently healthy female health professionals aged 45 years and older in the Women’s 
Health Study, a randomized trial of 100 mg aspirin every other day versus placebo." 
"MSMs, which adjusted for non-compliance, were similar for total CVD (HR = 0.93; 95 % CI: 0.81, 1.07) but 
suggested lower CVD mortality with aspirin use (HR = 0.76; 95 % CI: 0.54, 1.08)." 
“Marginal structural models (MSMs) [9] can be used to effectively adjust for time-varying confounding by nonfatal 
CVD events which are also affected by aspirin use.” 
 “MSMs were used to estimate the etiologic effect of aspirin in the presence of time-dependent  confounders that 
are themselves affected by previous aspirin use” 
 
ACTG 320: AIDS Clinical Trial Group; AIDS: Acquired Immune Deficiency Syndrome; ARISTOTLE: Apixaban for Reduction in Stroke and Other Thromboembolic 
Events in Atrial Fibrillation trial; CALERIE: Comprehensive Assessment of the Long-term Effects of Reducing Intake of Energy; MSM: marginal structural models; 
PHS: Physicians’ Health Study; PREDIMED: Primary Prevention of Cardiovascular Disease with a Mediterranean Diet; WHI: Women’s Health Initiative; WHS: 
Women’s Health Study   
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Webappendix 3 
Details of study results from main MSM-based and ITT-based analyses for main comparisons of the 12 trials 
ARISTOTLE  
The ARISTOTLE trial investigated the effect of apixaban versus warfarin in aspirin users and non-users on stroke or systemic embolism (Table 1). The main 
MSM-based result was a hazard ratio (HR) of 0.59 (95% CI 0.4 to 0.87) in aspirin users and a HR of 0.85 (95% CI 0.67 to 1.08) in aspirin non-users [24]. We 
identified an ITT analysis with a HR of 0.72 (95% CI 0.53 to 0.98) for aspirin users and a HR of 0.83 (95% CI 0.67 to 1.04) in aspirin non-users [41].  
Physicians’ Health Study (PHS)  
The Physicians’ Health Study (PHS) explored the effects of aspirin compared to placebo on cardiovascular mortality (Table 1). The main MSM-based result was 
a relative risk (RR) of 0.74 (95% CI 0.48 to 1.15) favoring aspirin [26]. The main ITT analysis was RR = 0.96 (95% CI 0.6 to 1.54) [28].  
Women’s Health Study (WHS) 
The Women’s Health Study (WHS) studied the effects of aspirin vs placebo on major cardiovascular events (Table 1). The main MSM-based result was a RR of 
0.93 (95% CI 0.81 to 1.07) [45]. The main ITT effect was a RR of 0.91 (95% CI 0.8 to 1.03) [27].  
Ranapurwala  
The study by Ranapurwala et al. assessed the effect of a pre-dive checklist on diving mishaps (Table 1). The main MSM-based result was a RR of 0.68 (95% CI 
0.5 to 0.93) [40]. The main ITT analysis was a RR of 0.8 (95% CI 0.58 to 1.08) [40].  
PREDIMED  
The PREDIMED study investigated the effect of Mediterranean diet supplemented with extra-virgin olive oil or nuts versus advice on a low-fat diet on major 
cardiovascular events (Table 1).MSM-based effects were only reported for the secondary outcome type 2 diabetes mellitus incidence. The MSM-based HR was 
0.7 (95% CI 0.52 to 0.94) for extra-virgin olive oil and 0.82 (95% CI 0.62 to 1.09) for nuts versus advice on a low-fat diet [23]. The according main ITT effects 
were HR 0.69 (95% CI 0.51 to 0.92) and 0.81 (95% CI 0.61 to 1.08), respectively [23]. 
Women’s Health Initiative (WHI)  
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The Women’s Health Initiative (WHI) explored the effect of estrogen-plus-progestin versus placebo in postmenopausal women with intact uterus on coronary 
heart disease (Table 1). The main MSM-based effect was a HR of 1.69 (95% CI 0.98 to 2.89) [29] and the main ITT effect was a HR of 1.29 (95% CI 1.02 to 1.63) 
[39].  
AIDS Clinical Trial Group 320 study (ACTG 320)  
The AIDS Clinical Trial Group 320 study (ACTG 320) compared the effect of zidovudine and lamivudine plus indinavir versus zidovudine and lamivudine alone 
on AIDS or death in HIV positive, immunosuppressed, ART-experienced patients (Table 1). The main MSM-based result was a HR of 0.45 (95% CI 0.27 to 0.74) 
[25]. The main ITT result was an HR of 0.5 (95% CI 0.33 to 0.76) [38]. 
POINTBREAK Study  
The POINTBREAK Study assessed the effect of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus maintenance 
bevacizumab on the overall survival of patients with lung cancer (Table 1). The main MSM-based result was the adaptively truncated MSM (truncating the 
longitudinal inverse-probability computations) with a HR of 1.12 (95% CI not reported) [46]. The main ITT result was a HR of 1.00 (95% CI 0.86 to 1.16) [43].  
Tunis / Faries  
The RCT reported by Tunis et al. [44] and Faries et al. [33] studied the effect of olanzapine or risperidone versus a “fail-ﬁrst” algorithm (conventional 
antipsychotics then olanzapine if indicated) on change in the brief psychiatric rating scale in patients with schizophrenia or a schizoaffective disorder (Table 1). 
The main MSM-based estimated treatment difference (olanzapine - conventional) was 1.9 (95% CI 0.5 to 3.3) [33] and the corresponding ITT estimated 
treatment difference was 0.2 (95% CI -1.8 to 2.1) [44].  
Negoro / Yamaguchi  
The RCT reported by Negoro et al. [42] and Yamaguchi et al. [32] explored the effect of irinotecan hydrochloride versus cisplatin in patients with lung cancer 
on overall survival (Table 1). An MSM-based effect was reported for overall survival in the subgroup of patients with stage IIIB lung cancer. The HR was 1.2 
(95% CI 0.64 to 2.28) [32]. The main ITT analysis was HR = 1.24 (95% CI 0.81 to 1.91) [42]. 
CALERIE Study 
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The CALERIE Study explored the effect of calorie restriction (behavioral approach with dietary modiﬁcations) versus no dietary restriction on resting metabolic 
rate (kcal/d) and core temperature (°C) in healthy young- and middle-aged non-obese men and women (Table 1). We used resting metabolic rate as main 
comparison. The main MSM-based mean difference was -36 (95% CI not reported) [31] and the corresponding ITT mean difference was -64 (95% CI not 
reported) [30].  
Kisumu RCT  
The Kisumu RCT assessed the effect of immediate versus delayed circumcision on HIV incidence (Table 1). The main MSM-based result was a HR of 0.42 (95% 
CI 0.26 to 0.66) over a 6-year follow-up. There were no ITT-based 6-year follow-up results available (planned duration of the trial was 2 years) [22]. Hence, this 
trial was not used in the main comparison of MSM vs ITT. 
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Discussion 
 
Overall findings  
In doctoral project I, we found that many observational studies in high impact journals lack satisfactory 
discussion of confounding bias. When confounding bias was mentioned, authors were often confident 
that it was rather irrelevant to their findings and they rarely called for cautious interpretation. Studies 
that discussed possible limitations due to confounding were actually cited more by other researchers 
than studies that deemed an influence due to confounding unlikely.  
In doctoral project II, we found that effects of the tested treatments in non-randomized studies using 
MSM often pointed in the opposite direction than when RCTs tested the treatments. Overall, MSM-
studies tended to show more favorable effects of the experimental treatment; this was more 
pronounced when the MSM-studies focused on informing health care decision making rather than 
statistical methodology.  
In doctoral project III, we found that MSM was thus far sometimes applied to RCTs, often to adjust for 
protocol deviations. They were typically not pre-specified, exploratory analyses. Within the main study 
publication and any corresponding publication reporting MSM-based results, trial authors reported on 
average 6 analysis results for one clinical question and the spread between the smallest and largest 
effect estimate can be substantial. The effect estimates of these analyses rarely pointed in different 
directions. MSM-effects and ITT-effects always pointed in the same direction (i.e. benefit or harm) with 
MSM-based results being more extreme (i.e. further from the null) in more than half of the cases, and 
differences in effect sizes were substantial in some cases. 
Findings in context 
Confounding bias is a pervasive threat to validity of non-randomized studies and deserves utmost 
attention. The assumption to know all confounding factors, to measure them correctly and to 
implement them correctly in the statistical models is very unrealistic. In light of the results of this 
doctoral thesis, major questions can be asked, including “How much impact does confounding have on 
healthcare decisions?” or “How should healthcare decision makers decide which estimate to trust in?”. 
There is no unified answer to the question how much impact confounding has. A simulation study 
found that the bias in the treatment effect estimate decreases or increases depending on the 
correlation of the confounders to each other (i.e. whether they consistently bias the effect in the same 
direction or not), the measurement error, the degree of unmeasured confounding, and the correlation 
between confounders with the exposure35. The impact of unmeasured confounding is greater when 
the confounders are not correlated as omitting even one confounder from the analysis can lead to 
substantial bias in the estimated effect35. When researchers try to minimize confounding and other 
biases in observational studies, the size of effect estimates, even the conclusions they draw, may still 
differ from those they would have obtained in an RCT, even when modern causal models are used 
(doctoral project II). However, the impact of confounding on the results is rarely discussed in the 
highest impact literature of general medical, epidemiologic, and specialty journals (doctoral project 
I)33. This is, however, clearly suggested by reporting guidelines, in particular by the Strengthening the 
Reporting of OBservational studies in Epidemiology (STROBE) guideline. A recent study evaluated the 
quality of reporting changes after the introduction of STROBE36. The authors concluded that despite 
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some improvements, the reporting quality of confounding remained overall suboptimal36. To improve 
the reporting beyond STROBE, the journal PLOS Medicine requires authors to complete the reporting 
checklist along with explanations how each item was accomplished37. Our findings highlight that such 
approaches may be urgently needed to improve the reporting of research results.  
There are many areas in healthcare where no RCT evidence is available and treatment decisions are 
made based on observational studies which rely on the assumption of no relevant confounding bias. 
The current use of observational research is often not clearly focused on such evidence gaps38. It is 
very likely that many health care decisions would be made differently if trials were available. 
Therefore, confounding bias has probably a huge impact on current health care, in particular in areas 
where no randomized trial evidence exists. 
Even in areas where trials support healthcare decisions, it is not always clear which result of the trial 
should be used to inform the decision. When multiple analyses (with or without addressing a specific 
type of confounding) are available for one outcome in an RCT, the spread between the smallest and 
largest effect estimate can be substantial (doctoral project III). Unclear reporting of multiple effect 
estimates on one clinical question makes it difficult for clinical decision makers to assess their role for 
the interpretation of results and to decide which estimate to base their decision on. In addition, due 
to the complexity of the underlying models, much more details are required to allow for replication of 
the studies.  
After all, depending on the clinical case at hand, even relatively small risk differences may be deciding 
over life and death. Hence, confounding should always be considered and minimized, if possible on 
design level2 39, and reporting needs to be as transparent as possible.  
 
Limitations and future research 
Despite applying various rigorous methods, the doctoral projects possess some limitations.  
First, in doctoral projects II and III, the analyzed sample was rather small. Our searches indicated that 
there are no trials for numerous clinical questions explored in observational MSM-studies but not in 
RCTs, which could be an explanation of the small sample of doctoral project II (as it depended on dyads 
of observational studies using MSM and RCTs on the same clinical question). The use of MSM in RCTs 
is relatively new and mostly used for explorative post-hoc analyses, which explains the small sample 
in doctoral project III. As the merits of this approach for RCTs may become clearer, so may the possible 
sample increase to allow for future replications or re-analyses. 
Second, we conducted the database searches only on PubMed40. However, there is no specific 
recommendation how many and which databases would be necessary to identify a representative 
sample for meta-epidemiological studies informing on research methodology. We applied a number 
of methods to improve the validity of our searches: we peer-reviewed the database searches on 
PubMed, we applied several measures to increase the retrieval rate of relevant studies, and conducted 
extensive prospective and retrospective citation searches (i.e. studies that have been cited by key 
literature or are citing key literature)41. 
Third, the research question of doctoral projects II and III was restricted to the application of MSM, 
and the implications do not necessarily generalize to other models for causal inference. While marginal 
structural models is one of the most frequently used methods for causal inference and to assess the 
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impact of time-varying confounding26, there are other methods to estimate treatment effects in the 
presence of time-varying confounders including g-computation formula and the g-estimation of 
structural nested models26. Acknowledging a steep increase in the use of these alternative methods, 
future research could address the agreement of different analysis methods correcting for time-varying 
confounding and compare it with standard methods.  
Fourth, we did not explore mechanistic reasons underlying our findings nor how to tackle some of the 
discovered issues, i.e. we cannot clearly answer the question why confounding was underestimated in 
the conclusions of observational research, why the application of MSM to non-randomized data does 
not always answer research questions as RCTs would, and why many RCTs report several different 
analysis methods for one and the same result without explanation. These could be addressed in future 
research, for example by investigating how well authors, editors, and teachers understand the 
meaning and impact of confounding. An international survey could help to identify the extent of the 
problem. Second, the results could provide the rationale for a world-wide campaign with the long-
term aim of improving research by promoting control for confounding as one of the basic principles of 
causal inference. 
Fifth, two of the three doctoral projects have not been published as journal article yet. However, we 
plan to (re-) submit in April 2018, also in light of the peer-review comments from the BMJ. However, 
some of the preliminary results were widely discussed on national and international meetings, 
including poster presentations and talks on the largest international conference in this area, the Global 
Evidence Summit of the Cochrane Collaboration, Campbell Collaboration, Guidelines-International 
Network, International Society for Evidence-based Health Care, and Joanna Briggs Institute in Cape 
Town, South Africa (September 2017), where I was awarded with the Thomas C. Chalmers award for 
the work on doctoral project II. In collaboration with my network of researchers from Switzerland, 
Germany, Austria, Brazil, USA, Canada, and Australia, I plan to further pursue the evaluation of 
confounding bias in health care and help to better address its implications for healthcare decision-
making. 
 
What we can do now 
There is plenty of things that can be done right now by users and producers of research evidence. 
Clinical decision makers should critically appraise the validity of research results and their applicability 
to the healthcare question at hand. They need to remain cautious when using non-randomized 
evidence, even when the most modern and complex models are applied. Researchers should 
acknowledge confounding more carefully in non-randomized and randomized research and when 
trying to answer questions that go beyond the pragmatic nature of the intention to treat. As we could 
show, acknowledgement of confounding is not associated with a lower citation impact and researchers 
do not need to fear to “perish” when publishing their results with adequate calls for caution. Before 
launching a trial, researchers should think critically about what they want to measure (including 
confounding variables), how they want to measure it and to ensure high quality data collection, and 
how bias, non-adherence, and loss-to-follow-up can be avoided. Adherence to a reporting guideline 
helps avoiding basic errors of reporting. Useful tools already exist, e.g. over 200 guidelines listed on 
the EQUATOR Network website (www.equator-network.org). With regard to current results, 
researchers should clearly state which analyses were pre-specified and which were explorative. 
Journals should make their policies clear and adhere to them.  
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Closing Remarks 
 
“Knowledge is merely brilliance in organization of ideas and not wisdom. The truly wise person goes 
beyond knowledge.” – Confucius42 
One issue with knowledge is the things we do not know. Semmelweis was laughed at, ignored at best, 
for his idea that organic particles from the autopsy room could cause the death of subsequently treated 
patients, especially women giving birth15. Without knowing the causal pathways, his hygienic measures 
had such a strong effect that eventually he convinced his peers of properly disinfecting their hands 
with chlorine solution before attending a delivery – with great life-saving effects. Yet, his explanation 
seemed too fantastic for the medical community and he received strong opposition15. Today, we know 
that these “particles” were bacteria and we found the means to see and measure them. Yet, the history 
of confounding is quickly forgotten when researchers succumb to the pressure of the current 
publication-based reward system rather than trying to evoke an overdue paradigm shift. This 
dissertation is a reminder to look beyond, to be realistic about the things we do not know, and to be 
open for the possibility that we got it all wrong: Do not make science an alternative fact.  
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Appendix I – Further Manuscripts published during doctoral studies 
 
Systematic review and simulation study of ignoring clustered data in surgical 
trials  
Br J Surg. 2018;105:182-91. 
Dell-Kuster S, Droeser RA, Schafer J, Gloy V, Ewald H, Schandelmaier S, Hemkens LG, Bucher HC, Young 
J, Rosenthal R 
Background: Multiple surgical procedures in a single patient are relatively common and lead to depen- 
dent (clustered) data. This dependency needs to be accounted for in study design and data analysis. A 
systematic review was performed to assess how clustered data were handled in inguinal hernia trials. 
The impact of ignoring clustered data was estimated using simulations.  
Methods: PubMed, Embase and the Cochrane Library were reviewed systematically for RCTs published 
between 2004 and 2013, including patients undergoing unilateral or bilateral inguinal hernia repair. 
Study characteristics determining the appropriateness of handling clustered data were extracted. 
Using simulations, various statistical methods accounting for clustered data were compared with an 
analysis ignoring clustering by assuming 100 hernias, with a varying percentage of patients having 
bilateral hernias.  
Results: Of the 50 eligible trials including patients with bilateral hernias, 20 (40 per cent) did not 
provide information on how they dealt with clustered data and 18 (36 per cent) avoided clustering by 
assessing the outcome by patient and not by hernia. None of the remaining 12 trials (24 per cent) 
considered clustering in the design or analysis. In the simulations, ignoring clustering led to an 
increased type I error rate of up to 12 per cent and to a loss in power of up to 15 per cent, depending 
on whether the patient or the hernia was the randomization unit.  
Conclusion: Clustering was rarely considered in inguinal hernia trials. The simulations underline the 
importance of considering clustering as part of the statistical analysis to avoid false-positive and false-
negative results, and hence inappropriate study conclusions. 
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Off-label treatments were not consistently better or worse than approved 
drug treatments in randomized trials  
J Clin Epidemiol. 2017. 
Ladanie A, Ioannidis JPA, Stafford RS, Ewald H, Bucher HC, Hemkens LG.  
Objectives: Off-label drug use is highly prevalent but controversial and often discouraged assuming 
generally inferior medical effects associated with off-label use. 
Study Design and Setting: We searched PubMed, MEDLINE, PubMed Health, and the Cochrane Library 
up to May 2015 for systematic reviews including meta-analyses of randomized clinical trials (RCTs) 
comparing off-label and approved drugs head-to-head in any population and on any medical outcome. 
We combined the comparative effects in meta-analyses providing summary odds ratios (sOR) for each 
treatment comparison and outcome, and then calculated an overall summary of the sOR across all 
comparisons (ssOR). 
Results: We included 25 treatment comparisons with 153 RCTs and 24,592 patients. In six of 25 
comparisons (24%), off-label drugs were significantly superior (five of 25) or inferior (one of 25) to 
approved treatments. There was substantial statistical heterogeneity across comparisons (I2 = 43%). 
Overall, off-label drugs were more favorable than approved treatments (ssOR 0.72; 95% CI = 0.54–
0.95). Analyses of patient-relevant outcomes were similar (statistical significant differences in 24% (six 
of 25); ssOR 0.74; 95% CI = 0.56–0.98; I2 = 60%). Analyses of primary outcomes of the systematic 
reviews (n = 22 comparisons) indicated less heterogeneity and no statistically significant difference 
overall (ssOR 0.85; 95% CI = 0.67–1.06; I2 = 0%). 
Conclusion: Approval status does not reliably indicate which drugs are more favorable in situations 
with clinical trial evidence comparing off-label with approved use. Drug effectiveness assessments 
without considering off-label use may provide incomplete information. To ensure that patients receive 
the best available care, funding, policy, reimbursement, and treatment decisions should be evidence 
based considering the entire spectrum of available therapeutic choices. 
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Comparative effectiveness of tenofovir in HIV-infected treatment-
experienced patients: systematic review and meta-analysis 
HIV Clin Trials. 2016:1-11. 
Ewald H, Santini-Oliveira M, Buhler JE, Vuichard D, Schandelmaier S, Stöckle M, Briel M, Bucher HC, 
Hemkens LG 
Background: Antiretroviral therapy (ART) regimens for HIV infection are frequently changed. We 
conducted a systematic review of randomized trials (RCTs) on the benefits and harms of switching to 
tenofovir disoproxil fumarate (TDF)-based regimens in ART-experienced patients.  
Methods: We included RCTs in HIV-infected adults comparing switching to a TDF-containing regimen 
with maintaining or switching to another regimen. We searched MEDLINE, EMBASE, CENTRAL, LILACS, 
SCI, and the WHO Global Health Library. We assessed bias with the Cochrane tool and synthesized data 
using random-effects meta-analyses and Peto’s approach. For further analyses, we added data from a 
previous systematic review in treatment-naïve patients. 
Results: 17 RCTs with 2210 patients were included. All but one study had a high risk of bias. There was 
no significant association of switching to TDF-based regimens with mortality, fractures, CD4-cell count, 
body fat, virological failure, LDL-, and HDL-cholesterol. TDF-based regimens decreased total cholesterol 
(mean difference −12.05 mg/dL; 95% CI −20.76 to −3.34), trigylcerides (−14.33 mg/dL; −23.73 to 
−4.93), and bone mineral density  (BMD;  hip:  −2.46%;  −3.9  to  −1.03;  lumbar  spine  −1.52%;  −2.69  
to  −0.34).  Effects on estimated glomerular filtration (eGFR) were inconsistent and depended on the 
measurement. Adding 22 RCTs from 8297 treatment-naïve patients gave consistent results with then 
significant reductions of LDL (−7.57 mg/dL; −10.37 to −4.78), HDL (−2.38 mg/dL; −3.83 to −0.93), and 
eGFR (−3.49 ml/min; −5.56 to −1.43). 
Conclusions: Switching to TDF-based regimens is associated with reductions of BMD and lipid levels 
and possibly lowered kidney function. The evidence is limited by the high risk of bias. 
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Colchicine and prevention of cardiovascular events 
JAMA. 2016;316(10):1106-1107. 
Hemkens LG, Ewald H, Briel M. 
JAMA Clinical Evidence Synopsis, no abstract available. 
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The clinical effectiveness of pneumococcal conjugate vaccines – a systematic 
review and meta-analysis of randomized controlled trials 
Dtsch Arztebl Int 2016; 113(9): 139-46; DOI: 10.3238/arztebl.2016.0139. 
Ewald H, Briel M, Vuichard D, Kreutle V, Zhydkov A, Gloy V. 
(English) 
Background: Streptococcus pneumoniae is responsible for approximately 1.6 million yearly deaths 
worldwide. An up-to-date evidence base on the effects of pneumococcal conjugate vaccines (PCVs)  on 
infectious diseases and mortality in any population or setting regardless of age or health status is 
currently lacking.  
Methods: We systematically searched MEDLINE and EMBASE for pertinent randomized controlled 
trials (RCTs). Two reviewers independently screened 9498 titles/abstracts and 430 full-text papers for 
eligible trials. The outcomes of our meta-analysis were pooled using relative risks (RRs) with a random 
effects model or Peto’s odds ratios (ORs) if event rates were <1%.  
Results: 21 RCTs comprising 361 612 individuals were included. PCVs reduced the risk for invasive 
pneumococcal disease (odds ratio [OR]: 0.43, 95% confidence interval [CI]: [0.36; 0.51]), all-cause acute 
otitis media (AOM) (RR: 0.93, 95% CI: [0.86; 1.00]), pneumococcal AOM (RR: 0.57, 95% CI: [0.39; 0.83]), 
all-cause pneumonia (RR: 0.93, 95% CI: [0.89; 0.97]), and pneumococcal pneumonia (RR: 0.78, 95% CI: 
[0.62; 0.97]). We found no significant effect of PCVs on all-cause mortality (RR: 0.95, 95% CI: [0.88; 
1.03]) or recurrent AOM (RR: 0.87, 95% CI: [0.72; 1.05]).  
Conclusion: PCVs are associated with large risk reductions for pneumococcal infectious diseases, 
smaller risk reductions for infectious diseases from any cause, and no significant effect on all-cause 
mortality. 
Klinische Wirksamkeit von Pneumokokken-Konjugatimpfstoffen – 
Systematische Übersichtsarbeit und Metaanalyse randomisierter 
kontrollierter Studien 
(German adaptation) 
Hintergrund: Streptococcus pneumoniae ist jährlich für rund 1,6 Millionen  Todesfälle weltweit 
verantwortlich. Derzeit gibt es keine systematische Übersichtsarbeit zu Pneumokokken-
Konjugatimpfstoffen (PCV), in der die Wirksamkeit in Bezug auf die Reduktion von 
Infektionskrankheiten und der Gesamtsterblichkeit in verschiedenen Populationen und Settings 
beurteilt wird.  
Methoden: Im Rahmen einer systematischen Literaturrecherche wurden  MEDLINE und Embase nach 
geeigneten randomisierten kontrollierten Studien (RCT) durchsucht. Zwei Autoren überprüften 
unabhängig voneinander 9 498 Titel/Abstracts und 430 Volltexte auf relevante Studien. Die Ergebnisse 
der Metaanalyse wurden als relative Risiken (RR) mit Random-Effects-Modellen, und bei Ereignisraten 
unter 1 % als Peto‘s Odds Ratios (OR) dargestellt. 
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Ergebnisse: Es konnten 21 RCT mit 361 612 Personen eingeschlossen werden. PCV reduzierten das 
Risiko für invasive Pneumokokken-Erkrankungen (OR: 0,43; 95-%-Konfidenzintervall [0,36; 0,51]), 
akute Otitis media (RR: 0,93 [0,86; 1,00]), Pneumokokken-spezifische akute Otitis media (RR: 0,57 
[0,39; 0,83]), Pneumonie (RR: 0,93 [0,89; 0,97]) und Pneumokokken-spezifische Pneumonie (RR: 0,78 
[0,62; 0,97]). Es zeigte sich kein signifikanter Effekt von PCV auf die Gesamtsterblichkeit (RR: 0,95 [0,88; 
1,03]) oder auf rezidivierende akute Otitis media (RR: 0,87 [0,72; 1,05]). 
Schlussfolgerung: Pneumokokken-Konjugatimpfstoffe sind mit großen Risikoreduktionen für 
Pneumokokken-spezifische Infektionskrankheiten, kleineren Risikoreduktionen für 
Infektionskrankheiten jedweder Ursache und keinem signifikanten Effekt auf die Gesamtsterblichkeit 
assoziiert. 
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Cardiovascular effects and safety of long-term colchicine treatment: 
Cochrane review and meta-analysis 
Heart 2016;0:1–7. 
Hemkens LG, Ewald H, Gloy VL, Arpagus A, Olu KK, Nidorf M, Glinz D, Nordmann AJ, Briel M. 
Colchicine is an old anti-inﬂammatory drug that has shown substantial cardiovascular beneﬁts in 
recent trials. We systematically reviewed cardiovascular beneﬁts and harms of colchicine in any 
population and speciﬁcally in patients with high cardiovascular risk. We evaluated randomised 
controlled trials comparing colchicine over at least 6 months versus any control in any adult population. 
Primary outcomes were all-cause mortality, myocardial infarction and adverse events. Cardiovascular 
mortality was a secondary outcome. We included 39 trials with 4992 patients. The quality of evidence 
for mortality outcomes and myocardial infarction was moderate but lower for adverse events. 
Colchicine had no effect on all-cause mortality (RR 0.94, 95% CI 0.82 to 1.09; I2=27%; 0 trials). 
Cardiovascular mortality was reduced in some but not all meta-analytical models (random-effects RR 
0.34, 0.09 to 1.21, I2=9%; Peto’s OR 0.24, 0.09 to 0.64, I2=15%; Mantel-Haenszel ﬁxed-effect RR 0.20, 
0.06 to 0.68, I2=0%; 7 trials). The risk for myocardial infarction was reduced (RR 0.20, 0.07 to 0.57; 2 
trials). There was no effect on total adverse events (RR 1.52, 0.93 to 2.46, I2=45%; 11 trials) but 
gastrointestinal intolerance was increased (RR 1.83, 1.03 to 3.26, I2=74%; 11 trials). Reporting of 
serious adverse events was inconsistent; no event occurred over 824 patient-years (4 trials). Effects in 
high cardiovascular risk populations were similar (4 trials; 1230 patients). We found no evidence 
supporting colchicine doses above 1 mg/day. Colchicine may have substantial cardiovascular beneﬁts; 
however, there is sufﬁcient uncertainty about its beneﬁt and harm to indicate the need for large-scale 
trials to further evaluate this inexpensive, promising treatment in cardiovascular disease. 
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Colchicine for prevention of cardiovascular events 
Cochrane Database Syst Rev. 2016;1:CD011047. 
Hemkens LG, Ewald H, Gloy VL, Arpagus A, Olu KK, Nidorf M, Glinz D, Nordmann AJ, Briel M. 
Background: Colchicine is an anti-inﬂammatory drug that is used for a wide range of inﬂammatory 
diseases. Cardiovascular disease also has an inﬂammatory component but the effects of colchicine on 
cardiovascular outcomes remain unclear. Previous safety analyses were restricted to speciﬁc patient 
populations.  
Objectives: To evaluate potential cardiovascular beneﬁts and harms of a continuous long-term 
treatment with colchicine in any population, and speciﬁcally in people with high cardiovascular risk. 
Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, 
EMBASE, ClinicalTrials.gov, WHO International Clinical Trials Registry, citations of key papers, and study 
references in January 2015. We also contacted investigators to gain unpublished data. 
Selection criteria: Randomised controlled trials (parallel-group or cluster design or ﬁrst phases of 
cross-over studies) comparing colchicine over at least six months versus any control in any adult 
population. 
Data collection and analysis: Primary outcomes were all-cause mortality, myocardial infarction, and 
adverse events. Secondary outcomes were cardiovascular mortality, stroke, heart failure, non-
scheduled hospitalisations, and non-scheduled cardiovascular interventions. We conducted 
predeﬁned subgroup analyses, in particular for participants with high cardiovascular risk. 
Main results: We included 39 randomised parallel-group trials with 4992 participants. Colchicine had 
no effect on all-cause mortality (RR 0.94, 95% CI 0.82 to 1.09; participants = 4174; studies = 30; I² = 
27%; moderate quality of evidence). There is uncertainty surrounding the effect of colchicine in 
reducing cardiovascular mortality (RR 0.34, 95% CI 0.09 to 1.21, I² = 9%; participants = 1132; studies = 
7; moderate quality of evidence). Colchicine reduced the risk for total myocardial infarction (RR 0.20, 
95% CI 0.07 to 0.57; participants = 652; studies = 2; moderate quality of evidence). There was no effect 
on total adverse events (RR 1.52, 95% CI 0.93 to 2.46; participants = 1313; studies = 11; I² = 45%; very 
low quality of evidence) but gastrointestinal intolerance was increased (RR 1.83, 95% CI 1.03 to 3.26; 
participants = 1258; studies = 11; I² = 74%; low quality of evidence). Colchicine showed no effect on 
heart failure (RR 0.62, 95% CI 0.10 to 3.88; participants = 462; studies = 3; I² = 45%; low quality of 
evidence) and no effect on stroke (RR 0.38, 95% CI 0.09 to 1.70; participants = 874; studies = 3; I² = 
45%; low quality of evidence). Reporting of serious adverse events was inconsistent; no event occurred 
over 824 patient-years (4 trials). Effects on other outcomes were very uncertain. Summary effects of 
RCTs speciﬁcally focusing on participants with high cardiovascular risk were similar (4 trials; 1230 
participants). 
Authors’ conclusions: There is much uncertainty surrounding the beneﬁts and harms of colchicine 
treatment. Colchicine may have substantial beneﬁts in reducing myocardial infarction in selected high-
risk populations but uncertainty about the size of the effect on survival and other cardiovascular 
outcomes is high, especially in the general population from which most of the studies in our review 
were drawn. Colchicine is associated with gastrointestinal side effects based on low-quality evidence. 
More evidence from large-scale randomized trials is needed.   
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Comparative effectiveness of Tenofovir in treatment-naïve HIV-infected 
patients: systematic review and meta-analysis 
HIV Clin Trials. 2015 Oct;16(5):178-89. 
Hemkens LG, Ewald H, Santini-Oliveira M, Bühler J-E, Vuichard D, Schandelmaier S, Stöckle M, Briel M, 
Bucher HC. 
Introduction: Beneﬁts and harms of tenofovir disoproxil fumarate (TDF) in HIV-infected, antiretroviral 
treatment (ART)-naïve patients of any age have not been systematically reviewed since recent 
milestone trials were published. 
Methods: We searched MEDLINE, EMBASE, CENTRAL, SCI, LILACS, WHO GHL, and ClinicalTrials.gov for 
randomized controlled trials (RCTs) comparing TDF-based treatments with any other ART-regimen (last 
search 01/2015). Trial characteristics and results were extracted, risks of bias systematically assessed, 
and treatment effects synthesized in meta-analyses using random-effects models. 
Results: We included 22 RCTs (8297 patients). We found no differences between groups for mortality, 
AIDS, fractures, CD4 cell count, and virological failure; and inconclusive information due to inadequate 
reporting for cardiovascular events, renal failure, proteinuria, rash, and quality of life. Tenofovir 
disoproxil fumarate-based regimens signiﬁcantly reduced total cholesterol (mean difference { 18.42 
mg/dl; 95% conﬁdence interval [CI] { 22.80 to { 14.0), LDL-cholesterol ( { 9.53 mg/dl; { 12.16 to { 6.89), 
HDL-cholesterol ( { 2.97 mg/dl; { 4.41 to { 1.53), and triglycerides ( { 29.77 mg/dl; { 38.61 to { 20.92), 
bone mineral density (BMD) (hip: { 1.41%; { 1.87 to { 0.94), and glomerular ﬁltration rate (eGFR) ( { 3.47 
ml/minute; { 5.89 to { 1.06) over 48 weeks of follow-up. Effects were similar in trials comparing ﬁxed-
dose TDF/FTC-based regimens with ABC/3TC-based regimens. We found no inﬂuence of baseline viral 
load on virological failure. 
Discussion: Moderate-quality evidence suggests similar effects of TDF-based treatment regimens and 
other ART on virological failure. Tenofovir disoproxil fumarate-based regimens are associated with a 
more favorable lipid proﬁle, but with increased risk of reduced BMD and eGFR. Improved reporting 
quality is vital to allow assessment of clinical outcomes in future trials.  
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Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients 
with HIV infection 
Cochrane Database of Systematic Reviews 2015, Issue 4. Art. No.: CD006150. DOI: 10.1002/14651858. 
CD006150.pub2. 
Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M. 
Background: Pneumocystis jiroveci pneumonia (PCP) remains the most common opportunistic 
infection in patients infected with the human immunodeﬁciency virus (HIV). Among patients with HIV 
infection and PCP the mortality rate is 10% to 20% during the initial infection and this increases 
substantially with the need for mechanical ventilation. It has been suggested that corticosteroids 
adjunctive to standard treatment for PCP could prevent the need for mechanical ventilation and 
decrease mortality in these patients.  
Objectives: To assess the effects of adjunctive corticosteroids on overall mortality and the need for 
mechanical ventilation in HIV-infected patients with PCP and substantial hypoxaemia (arterial oxygen 
partial pressure < 70 mmHg or alveolar-arterial gradient > 35 mmHg on room air). 
Search methods: For the original review we searched The Cochrane Library (2004, Issue 4), MEDLINE 
(January 1980 to December 2004) and EMBASE (January 1985 to December 2004) without language 
restrictions. We further reviewed the reference lists from previously published overviews, searched 
UptoDate version 2005 and Clinical Evidence Concise (Issue 12, 2004), contacted experts in the ﬁeld 
and searched the reference lists of identiﬁed publications for citations of additional relevant articles. 
In this update of our review, we searched the above-mentioned databases in September 2010 and 
April 2014 for trials published since our original review. We also searched for ongoing trials in 
ClinicalTrials.gov and the World Health Organization International Clinical Trial Registry Platform 
(ICTRP). We searched for conference abstracts via AEGIS. 
Selection criteria: Randomised controlled trials that compared corticosteroids to placebo or usual care 
in HIV-infected patients with PCP in addition to baseline treatment with trimethoprim-
sulfamethoxazole, pentamidine or dapsone-trimethoprim, and reported mortality data. We excluded 
trials in patients with no or mild hypoxaemia (arterial oxygen partial pressure > 70 mmHg or an 
alveolar-arterial gradient <35 mmHg on room air) and trials with a follow-up of less than 30 days. 
Data collection and analysis: Two teams of review authors independently evaluated the methodology 
and extracted data from each primary study. We pooled treatment effects across studies and 
calculated a weighted average risk ratio of overall mortality in the treatment and control groups using 
a random-effects model. In this update of our review, we used the GRADE methodology to assess 
evidence quality. 
Main results: Of 2029 screened records, we included seven studies in the review and six in the meta-
analysis. Risk of bias varied: the randomization and allocation process was often not clearly described, 
ﬁve of seven studies were double-blind and there was almost no missing data. The quality of the 
evidence for mortality was high. Risk ratios for overall mortality for adjunctive corticosteroids were 
0.56 (95% conﬁdence interval (CI) 0.32 to 0.98) at one month and 0.59 (95% CI 0.41 to 0.85) at three 
to four months of follow-up. In adults, to prevent one death, numbers needed to treat are nine patients 
in a setting without highly active antiretroviral therapy (HAART) available, and 23 patients with HAART 
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available. The three largest trials provided moderate quality data on the need for mechanical 
ventilation, with a risk ratio of 0.38 (95% CI 0.20 to 0.73) in favour of adjunctive corticosteroids. One 
study was conducted in infants, suggesting a risk ratio for death in hospital of 0.81 (95% CI 0.51 to 1.29; 
moderate quality evidence). 
Authors’ conclusions: The number and size of trials investigating adjunctive corticosteroids for HIV-
infected patients with PCP is small, but the evidence from this review suggests a beneﬁcial effect for 
adult patients with substantial hypoxaemia. There is insufﬁcient evidence on the effect of adjunctive 
corticosteroids on survival in infants. 
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